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Abstract
Lower back pain (LBP) is one of the most common conditions worldwide, yet, current
therapeutics are limited to symptomatic relief and do not directly treat the underlying cause
of pain. This is largely due to an incomplete understanding of the biological pathways and
tissues involved in LBP. While many tissues appear to be involved, intervertebral disc
(IVD) degeneration is believed to be a major contributor.
The main aim of this thesis was to characterize the role of two environmental risk factors,
mechanical loading and obesity, in the initiation of IVD degeneration and associated pain
using the mouse as a preclinical model. We first investigated the effects of mechanical
loading, specifically whole-body vibration (WBV), on joint health. In contrast to previous
findings in CD-1 mice, we show that WBV delivered using parameters that model those
used clinically does not affect joint health in C57BL/6 mice . These findings suggest that
the response of joint tissues to WBV may vary in a strain-specific manner.
We next evaluated the impact of diet-induced obesity on IVD degeneration and associated
pain. Ten-week-old male C57BL/6N mice were fed either a control, high-fat, or western
diet for 12, 24 or 40 weeks. At endpoint, mice were assessed for behavioral indicators of
pain and histological and molecular analyses were carried out on joint and neural tissues.
We demonstrated that diet-induced obesity accelerates IVD degeneration; however, painrelated behaviors precede histological joint damage.
Finally, we examined the role of peroxisome proliferator-activated receptor delta (PPARδ)
as a potential mediator of IVD degeneration. We confirmed that PPARδ was expressed and
functionally active in the IVD and used male and female, cartilage-specific Ppard knockout
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(Ppard KO) mouse to assess age- and obesity-associated IVD degeneration. Loss of
PPARδ appeared to be protected against age-associated IVD degeneration; however, this
protective effect was not observed with obesity-induced IVD degeneration or knee
osteoarthritis.
Overall, this data highlights the complex interactions between modifiable and nonmodifiable risk factors as drivers of IVD degeneration and associated back pain.
Furthermore, these studies highlight the importance of including sex as a biological
variable and assessing pain and IVD degeneration, as they do not always correlate.

Keywords: Intervertebral disc degeneration; Back pain; Whole-body vibration; Obesity;
Peroxisome proliferator activated receptor delta (PPARδ); Mouse models.
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Summary for Lay Audience
Lower back pain (LBP) is one of the most common causes of disability worldwide, yet
current treatments are limited to pain relief and do not directly treat the underlying cause
of pain. This is largely due to an incomplete understanding of what tissues contribute to
LBP and why pain occurs. Large-scale association studies in humans have identified
several risk factors for the development of LBP including age, genetics, mechanical
loading and obesity; however, how and why they cause the pain is largely unknown.
While many tissues appear to be involved in LBP, intervertebral disc (IVD) degeneration
is believed to be a major contributor in many cases. IVDs are specialized joints located
between the vertebrae in the spine that act as shock absorbers, helping to dissipate
mechanical loading. Degeneration is a progressive biological process that results in the
functional failure of the tissue and can result in pain. This research was designed to
investigate the impact of mechanical loading, specifically whole-body vibration (WBV),
and obesity on IVD degeneration and associated pain using the mouse as a model system.
Furthermore, we investigate a potential biological mediator to explain how obesity impacts
IVD degeneration and associated pain.
In our first study we demonstrate that the response of joint tissues to WBV vary based on
genetic background of the animals. In our second study we demonstrated that diet-induced
obesity does accelerate IVD degeneration and pain-related behavior in a mouse model;
however, pain related behaviors precede structural IVD damage. Lastly, we assessed a
potential biological mediator of IVD degeneration - peroxisome proliferator activated
receptor delta (PPARδ) – in aging and obesity. Using mice that had the PPARδ gene deleted
in joint tissues, we showed that loss of PPARδ protected against age-associated IVD
iv

degeneration; however, this protective effect was not observed with obesity-induced IVD
degeneration.
Taken together, this thesis highlights the complex interactions between mechanical loading
and obesity as drivers of IVD degeneration and associated back pain. Furthermore, these
studies highlight the importance of including sex as a biological variable and assessing pain
and IVD degeneration, as they do not always correlate.
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Chapter 1

1

Introduction

1.1

What is pain?

The International Association for the Study of Pain defines pain as “an unpleasant sensory
and emotional experience associated with actual or potential tissue damage or described in
terms of such damage”1. The ability to detect noxious and potentially dangerous stimuli is
essential to avoid tissue injury and facilitate healing. While pain is unpleasant, it is essential
for overall survival and wellbeing2. This is highlighted in individuals that have congenital
insensitivity to pain. These individuals cannot feel broken bones, heat from a fire or being
cut. As a result, they are not aware of potentially life-threatening injuries and do not know
when to take appropriate protective behaviors3.

1.1.1

Biological mechanisms of pain

Pain is a multidimensional, dynamic interaction between biological, psychological, and
social factors that influence one another and can contribute to how a person interprets
noxious stimuli signaling tissue injury4. At the biological level, nociception is the process
by which information about actual or potential tissue damage is relayed to the brain5. These
signals are initiated at specialized receptors called nociceptors, which are attached to thin
myelinated Aδ fibers and unmyelinated C-fibers that transmit the signal to the brain6. At
the site of injury these nociceptors become activated by chemical activation or mechanical
and thermal stimuli2, leading to the opening of voltage-gated sodium and potassium
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channels2. The opening of these channels forms an action potential, which is then
propagated to the dorsal horn of the spinal cord and ultimately the brain2.

1.1.2

Acute vs. Chronic pain

While acute pain plays a physiological role in response to tissue damage, chronic pain is
defined as “pain that persists past the normal time of healing”, which, in the context of
back pain, is typically over 3 months in duration 7. Chronic pain conditions are one of the
most common reasons people seek medical care, and have been linked with decreased
quality of life, decreased mobility, and the development of psychiatric conditions such as
depression and anxiety8–11. Chronic pain conditions have a large socioeconomic effect,
affecting up to 40% of Canadians12. Chronic pain costs the Canadian taxpayer more than
cancer and heart disease combined, with direct healthcare costs at $6 billion a year13,14 and
indirect costs estimated at $37 billion a year13. Uncontrolled pain is the most common cause
of disability amongst working-age adults in Canada, and up to 60% of people living with
chronic pain lose their jobs14,15.
While the precise mechanisms associated with the transition from acute to chronic pain are
largely unknown, several potential mediators have been implicated including peripheral
and central sensitization. Peripheral sensitization involves increased excitability of the
primary afferent nociceptors, resulting in a decreased threshold for action potential
generation or the generation of spontaneous action potentials without the presence of a
noxious stimuli16,17. While many biological mechanisms can contribute to peripheral
sensitization, inflammatory mediators secreted at the site of injury can change the
properties of nociceptors5,18. Nerve growth factor (NGF) appears to be one key mediator
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driving peripheral sensitization through both direct actions on the nociceptors and indirect
actions on surrounding tissues. NGF is a neurotrophin released by many cell types,
including inflammatory cells, at the site of tissue injury19,20. NGF exerts its actions through
binding with its receptor, Tropomyosin-related kinase A receptor (TrkA), activating a
series of downstream signaling pathways. NGF-TrkA activation on nociceptors leads to
rapid sensitization of the neuron through intracellular signaling cascades that results in
increased expression and phosphorylation of channels and receptors involved in pain
transduction21,22. NGF-TrkA activation also leads to a prolonged increase in the expression
of neuropeptides, receptors and ion channels involved in pain transmission 23.
Central sensitization can also contribute to chronic pain. Central sensitization is caused by
increased excitability of second order neurons within the spinal cord that transmit the
nociceptive signals from the primary afferent neurons to the brain17,24. This increased
excitability within the central nervous system can contribute to the lack of a direct
correlation between nociceptor activation and painful experience17. Several mechanisms
contribute to central sensitization including increased neuronal membrane excitability,
facilitated synaptic transmission, and disinhibition of second order neurons25. While
neuropeptides released from nociceptive neurons contribute to central sensitization, glial
cells (astrocytes and microglia) within the spinal cord also play an important role in this
process26. Astrocytes are the most abundant cell type within the brain and perform a variety
of different functions including, but not limited to, regulating synaptic transmission and
providing metabolic support to neurons27,28. However, in cases of chronic pain and
neuroinflammation, these cells undergo a phenotypic switch to a so called “state of
activation” marked by increased production of the astrocyte-specific marker glial fibrillary
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acidic protein (GFAP), and an enlargement of the astrocyte processes26. Activated
astrocytes have decreased glutamate reuptake and release neuromodulators that can alter
synaptic transmission within the spinal cord26. Microglia, which are the resident
macrophages in the spinal cord, are also activated in chronic pain conditions and contribute
to central sensitization26. Activated microglia release pro-inflammatory cytokines that
further modulate synaptic activity by altering the activity and expression of ion channels
and receptors26. While both peripheral and central sensitization are potential mediators of
chronic pain, it should be noted that pain is a biopsychosocial experience that has sensory,
affective, and cognitive components that contribute to the interpretation of nociceptive
signals, and whether the signals coming into the brain are perceived as pain5.

1.2

Back pain is a problem

The most recent Global Burden of Disease study reported back pain as the single most
common cause of disability worldwide, with a lifetime prevalence of over 84% in
developed countries29. While 90% of people recover from acute episodes of lower back
pain (LBP) within a few months, some will not recover and instead develop chronic
LBP30,31. Chronic LBP is debilitating physically as well as socially. People suffering from
LBP report feeling hopelessness, loss of identity and social isolation, which can lead to
depression and suicide ideation32,33. Like other chronic pain conditions, chronic LBP has a
large impact at the societal level as well. In the United States, LBP costs the economy an
estimated $100 billion a year in both direct (primary care, pharmaceuticals, etc.) and
indirect costs (lost wages, reduced productivity)34. Several tissues appear to be involved in
chronic LBP, including muscles, ligaments, facet joints, nerve roots, vertebral bones, and

5

the intervertebral discs (IVDs)35. Of these, pain arising from IVD degeneration – termed
discogenic back pain - is believed to be the major contributor to pain in an estimated 40%
of cases36,37. Current therapeutic interventions focus on providing symptomatic relief, but
do not address the underlying cause of the pain38, or restore the mechanical function of the
tissue39. Altered mechanical function of the tissue can accelerate IVD degeneration in
adjacent spinal levels, which can further contribute to pain and disability40,41. Our ability
to treat IVD degeneration is limited due to an incomplete understanding of molecular
processes that regulate IVD homeostasis and disease.

1.3

The Spine

In humans, the spine has 3 main functions: protect the spinal cord and nerve roots, provide
structural support to maintain balance and upright posture, and enable flexible motion42.
Anatomically, the spine consists of an osseous vertebral column surrounded by
musculature and connective tissues that aid in the overall function of the structure (Figure
1.1). The basic functional unit of the spine is called a motion segment, consisting of a single
intervertebral disc, the inferior and superior vertebrae and associated connective tissue43.

1.3.1

Vertebral bone

In humans, the vertebral column is composed of 24 presacral vertebrae separated by 23
intervertebral discs (IVDs), subdivided into three anatomical regions: cervical (7
vertebrae, 6 IVDs), thoracic (12 vertebrae, 12 IVDs) and the lumbar region (5 vertebrae,
5 IVDs)44. In mice, the vertebral column is composed of 7 cervical, 13 thoracic, 6 lumbar,
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Figure 1.1: Schematic depiction of the major components of the spine.
The spine is composed of several different tissues that are essential for its overall function.
These include osseous vertebrae, fibrocartilaginous intervertebral discs, muscles, and
ligaments. The spine also serves structurally to surround the spinal cord. The spinal cord
is a component of the central nervous system that transmits motor and sensory information
between the brain and the peripheral nervous systems.
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4 sacral, and 28 caudal (tail) vertebrae45. While the osseous features of each vertebrae are
generally preserved in the different anatomical areas, their morphology differs slightly and
contribute to the biomechanical stability and flexibility of the vertebral column44.

1.3.2

The Intervertebral Disc

The intervertebral disc (IVD) is a fibrocartilaginous joint that links vertebral bodies along
the spine and allows for spine flexibility and stability under axial compression46.
Anatomically, the IVD is a heterogeneous structure composed of three distinct, yet
interdependent tissues. At the core of the IVD lies the gelatinous nucleus pulposus (NP),
surrounded by the fibrocartilaginous annulus fibrosus (AF), and cartilage endplates that
anchor the IVD to adjacent vertebrae (Figure 1.1). Each tissue is structurally and
mechanically unique, but closely coupled with one another to contribute synergistically to
the function of the IVD47.

1.3.2.1

Nucleus Pulposus

At the center of the IVD lies the nucleus pulposus (NP), a gelatinous tissue composed of
proteoglycans and water held together by an irregular network of type II collagen48.
Although the NP contains several different types of proteoglycans such as decorin,
versican, and biglycan, the major proteoglycan in the NP is aggrecan48,49. These
proteoglycan core proteins are covalently bound by glycosaminoglycans (GAGs), such as
chondroitin sulfate and keratin sulfate, that act to draw water into the NP thereby
contributing to its osmotic properties and ability to dissipate compressive loads48,50,51 .
Aggrecan also has the ability to form proteoglycan aggregates, in which many aggrecan
molecules interact with hyaluronan via link protein, which limits their diffusion through
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the tissue, allowing for an even distribution of load across the NP51,52. Within the NP
there are two different cell types that contribute to extracellular matrix (ECM)
production: notochord cells and cartilage-like NP cells. During development, notochord
cells are the major cell type in the NP and produce a proteoglycan rich ECM53,54. In
humans, the number of notochord cells within the NP steadily decrease with age, and the
NP is populated instead by cartilage-like NP cells55 that secrete an altered ECM 53.
Functionally, the role of the NP is to dissipate compressive loading between adjacent
vertebral segments of the spine. This is facilitated through the osmotic pressure created
by the anionic side chains attached to proteoglycan, which act to draw in water to this
tissue46,47. The NP’s ability to dissipate compressive loading is dependent on the radial
forces of the surrounding annulus fibrosus56.

1.3.2.2

Annulus Fibrosus

The fibrocartilaginous annulus fibrosus (AF) encapsulates the gelatinous NP. The major
component of the AF ECM is collagen, with lower levels of proteoglycans compared to
the NP57. In the AF, the collagen fibers run in parallel to one another within distinct lamella.
In humans, the AF is arranged in 15-25 concentric lamellae, where collagen fibers of
adjacent lamellae travel in opposite directions at oblique angles, to form an angle-ply
structure providing tensile strength56,58,59. The AF is typically divided into the outer AF
and the inner AF, which have different ECM components. The outer AF is composed
largely of type I collagen and elastic fibers, helping the tissue to dissipate tensile load56,60.
This is in contrast to the inner AF, which serves as a transition between the
fibrocartilaginous outer AF and the NP, and has a higher type II collagen and proteoglycan
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content within the interlamellar matrix than the outer AF; a feature that provides resistance
to compressive loading56,61. Similar to the ECM composition, the cellular morphology and
biochemical profiles of the cells are different based on anatomical location within the AF62.
Cells in the inner AF have more of a rounded, chondrocyte-like morphology compared to
the spindle-shaped, fibroblast-like cells of the outer AF62. The difference in cellular profiles
across this tissue are thought to arise from variations in mechanical loading seen across the
tissue, where cells of the inner AF are exposed to compression and tension and the cells of
the outer AF are exposed to predominantly tension63,64. Functionally, the role of the AF is
to support the radial forces exerted by the NP63, which requires the tissue to be able to resist
tensile loading and depends on the microarchitecture of the collagen network47.

1.3.2.3

Cartilage endplates

The cartilage endplates (CEP) are thin layers of hyaline cartilage at the superior and inferior
ends of the IVD57. Similar to articular cartilage, the CEP is composed mostly of water,
followed by type II collagen and proteoglycans57,65. The collagen fibrils within the CEP
are arranged differentially based on location within the CEP, but merge with collagen fibers
of the AF at the margins of the IVD56. The cells of the CEP are very similar in morphology
and density to articular chondrocytes, yet, no zonal arrangement is seen within the CEP66.
The main role of the CEP is to act as a semi-permeable barrier. While the outer lamellae of
the AF is vascularized, the NP is completely avascular and depends on diffusion through
the CEP for nutrient supply67.

The vertebral bone underlying the CEP is highly

vascularized, allowing for the diffusion of small molecules such as oxygen and glucose
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into the IVD67. With age, the CEP can become calcified, thereby impairing the diffusion
of solutes into the IVD; a process thought to drive IVD degeneration67,68.

1.3.3

Muscle and connective tissue

Muscle and connective tissues (i.e. ligaments and tendons) connect to the vertebral bodies
at a number of anatomical landmarks and play a major role in movement as well as
supporting the axial skeleton in an upright posture69,70. Muscle specifically plays a very
important role in supporting the spine against forces seen in everyday life71. Muscular
dysfunction, whether due to muscle weakness or impaired neurological coordination,
contributes to decreased stability of spinal structures, leading to gradual degeneration of
joints and soft tissue over time, potentially contributing to LBP71,72. Clinically, atrophy of
paraspinal muscles (e.g. multifidus muscle) has been associated with chronic LBP73,
however, it is difficult to determine whether this is a cause or consequence of pain.

1.3.4

Innervation & Vascularization

In the lumbar spine, the vertebral bodies, muscles and ligaments are innervated by several
different nerves including the sinuvertebral nerves, ventral rami, dorsal rami, and gray
rami74,75. While lumbar IVDs receive innervation from some of the same neural sources
(sinuvertebral nerve, dorsal rami) 76, the presence of nerves is restricted to the outermost
layers of the AF in healthy tissues77,78. The lumbar spine receives its blood supply from
several sources, including the lumbar, middle sacral, and branches of the iliolumbar
arteries79. While the tissues surrounding the IVD are well vascularized, only the outmost
layers of the AF receive direct vascular supply80.
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1.4

Intervertebral Disc Degeneration

IVD degeneration has been defined as an aberrant, cell-mediated response leading to
progressive structural failure81. It involves a progressive cascade of events, beginning with
changes to the IVD microenvironment and eventually resulting in structural breakdown
and functional impairment of the tissue 39. Disc degeneration is characterized by increased
ECM breakdown and abnormal (fibrotic) matrix synthesis leading to reduced hydration,
loss of disc height, and decreased ability to absorb load50,82. As mentioned previously, IVD
degeneration is believed to be the primary contributor to chronic LBP in an estimated 40%
of cases36. IVD degeneration is distinguished from disc herniation, which is associated with
a tear of the AF (often associated with acute injury), leading to extrusion of the NP into the
space surrounding the IVD also resulting in pain83.

1.4.1

Risk factors for IVD degeneration

Risk factors for IVD degeneration include non-modifiable risk factors such as genetics, age
and sex, as well as modifiable/environmental risk factors such as obesity, mechanical
loading, and smoking. It should be noted that these risk factors are not mutually exclusive,
and individuals can have multiple risk factors contributing to disease progression.
Moreover, IVD degeneration is likely a group of diseases with distinct etiologies yet a
common radiographic presentation.

1.4.1.1

Non-modifiable risk factors

Genetic predisposition is the largest risk factor for IVD degeneration, followed by
age50,84,85. With the advance in genetic technologies, genome-wide association studies

12

have highlighted several gene variants as risk factors for the development of IVD
degeneration. Many of these genes encode for proteins involved in ECM homeostasis
including collagen I, collagen IX, aggrecan, matrix metalloproteinase-3 (MMP-3) amongst
many others86,87. Polymorphisms in the coding region of these matrix components may
lead to altered protein products, functional impairment, and ultimately accelerated IVD
degeneration. For example, polymorphisms within aggrecans coding region are believed
to decrease the number of GAG binding sites, impairing the hydrophilic nature of the
molecule. This is thought to contribute to IVD degeneration through decreased hydration
of the IVD, reducing its ability to dissipate compressive load88. While polymorphisms
within intronic and exonic regions of single genes have been associated with IVD
degeneration, it is believed that IVD degeneration is likely polygenic, where minor
variations within several genes work synergistically to contribute to disease progression89–
92

. In addition to genetic predisposition, age and sex are also established risk factors for

IVD degeneration93,94. In humans, IVD degeneration accelerates linearly during the fifth
decade of life94, with potential causes being loss of nutrition caused by CEP calcification,
cellular senescence, and accumulation of degraded ECM50,67,93. In addition, females show
an increased risk of developing IVD degeneration (Odds Ratio [OR], 1.69 when adjusted
for age) compared to males, although biological mechanisms underlying this association
are currently unknown95.

1.4.1.2

Modifiable risk factors

Life-style related risk factors have been shown to have a large impact on IVD health. These
risk factors include mechanical loading, obesity, shift work and smoking81,96,97. Mechanical

13

loading plays a major role in IVD cell function47, and mechanical overloading can promote
processes associated with IVD degeneration including induction of catabolic gene
expression and cell death98. In humans, increased loading is associated with IVD
degeneration, through

occupational

hazards99

or recreational

sports such

as

weightlifting100. Increased mechanical loading on the IVD is also seen in obesity, which is
a risk factor for both structural IVD degeneration and LBP101,102. However, this link
between obesity, IVD degeneration, and LBP is likely multifactorial, involving both
mechanical and metabolic components103. The exact mechanisms by which these
modifiable risk factors contribute to IVD degeneration are still being explore, but their
impact can be reduced through life-style modifications and education.

1.4.2

Pathogenesis of IVD degeneration

Cells of the IVD are necessary to produce, maintain and repair the extensive ECM needed
for the IVD to be functional. With IVD degeneration, cells undergo substantial biological
changes including altered cellular phenotype, senescence, and apoptosis, that may
contribute to disease progression53. Cellular senescence – the irreversible arrest of cell
proliferation104 – is increased in IVD degeneration105. Alongside reduced proliferative
capacity of these cells, there are also alterations in cellular function and phenotype. In
human IVD cells, markers of senescence positively correlate with increased expression of
matrix degrading enzymes such as MMP13 and ADAMTS5, which mediate matrix
degradation in IVD degeneration106. While senescence naturally occurs during aging
through telomere shortening, it can be accelerated by stress signals such as the proinflammatory cytokine interleukin 1 (IL-1), which is also associated with IVD
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degeneration107,108. However, it is unlikely that all phenotypic differences associated with
IVD degeneration are due to cellular senescence, as reversible changes can be caused by
environmental signals such as mechanical loading53. During IVD degeneration, cells
produce increased levels of inflammatory and catabolic factors, decrease synthesis of
normal ECM components (type II collagen, aggrecan), increase synthesis of fibrotic matrix
components (type I collagen), and alter secretion of growth factors that can potentiate the
degenerative process53. In addition to alterations in the phenotype of remaining IVD cells,
IVD degeneration is also associated with increased levels of cell apoptosis109. Together
these factors decrease the number of properly functioning cells needed to maintain and
repair the ECM, potentially accelerating IVD degeneration.
Alterations in cellular function associated with IVD degeneration is marked by increased
production

of

factors

that

accelerate

ECM

degradation,

including

matrix

metalloproteinases (MMPs) and ‘a disintegrin and metalloproteinase with thrombospondin
modifs’ (ADAMTS)110. MMP-1,-2,-3,-7,-12,-13 are upregulated in human IVD
degeneration110–112, and degrade a number of ECM components, including collagens type
I and II, as well as non-collagenous proteins such as aggrecan113. ADAMTS-4, and -5 are
also upregulated in IVD degeneration113,114. Unlike the MMPs, ADAMTS enzymes
demonstrate a narrow substrate specificity; ADAMTS-4, and -5 primarily cleave aggrecan,
and their increased activity leads to the accumulation of fragmented proteoglycans within
the IVD114. While not directly investigated in the IVD, these proteoglycan fragments
potentiate inflammatory processes in articular cartilage through activation of toll-like
receptors, and may therefore likewise accelerate IVD degeneration115. In addition to matrix
degrading enzymes, IVD cells intrinsically produce and secrete inflammatory cytokines
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and neurotrophins such as IL-1β, IL-6, Tumor Necrosis Factor alpha (TNF α), NGF, which
are all elevated with IVD degeneration78,108,116. Aside from their pro-nociceptive roles on
nerve roots93,117, these inflammatory cytokines can potentiate pathways leading to
increased expression of many of the catabolic enzymes mentioned above including MMP1,-3,-13 and ADAMTS-4,-5108. As a result of ECM breakdown and an altered secretion of
matrix components, the biomechanical properties of the IVD are impaired50,118. As the NP
becomes less hydrated and more fibrous, it is no longer able to dissipate compressive loads
effectively, resulting in increased transfer of load to the AF118. Increased AF mechanical
loading in turn leads to structural degeneration of the AF119.
Lastly, IVD degeneration is associated with vascular and neural ingrowth into the normally
avascular and aneural tissue120,121. It has been suggested that this neural ingrowth is an
important contributor to discogenic pain, which is pain originating from the IVD120,122.
While the mechanisms responsible for nerve ingrowth into the IVD are largely unknown,
ECM breakdown and neurotrophins are believed to play an important role78. In healthy
IVDs, aggrecan has been shown to inhibit nerve ingrowth, however, when IVDs
degenerate, loss of intact aggrecan may result in nerve ingrowth78,123. This appears to be
coupled with increased expression of proinflammatory cytokines such as IL-1β, TNFα and
IL-4 inducing the expression of the NGF, which can directly stimulate nociceptive afferents
and cause further ingrowth of nociceptive nerve fibers into the IVD78.
Once the process of IVD degeneration has started, it is difficult to stop. A recent review
describes IVD degeneration as a vicious circle, where abnormal interactions between
biomechanics, cellular processes, and ECM components result in a positive feedback loop
resulting in accelerated IVD degeneration (Figure 1.2) 119. An alteration in any of these
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Figure 1.2: Proposed feed forward model of intervertebral disc degeneration with
contributing risk factors.
Intervertebral disc homeostasis is dependent on interactions between cells, extracellular
matrix, and biomechanics of the spine. Alterations in any of these factors alter the others
and can initiate the degenerative cycle. For an example, upregulation of catabolic genes
(i.e. Mmp3, Mmp13, Adamts4, Adamts5) from the cells of the IVD – perhaps caused by
aberrant mechanical loading or obesity - would lead to the degradation of the extracellular
matrix, thereby altering the biomechanical properties of the IVD. Alterations in tissue
mechanics would then alter the mechanical loads experienced by cells, causing further
alterations to cellular function. Figure modified from118; Asterix indicate risk factors
assessed in the current thesis.
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elements may initiate IVD degeneration, ultimately leading to structural and functional
failure of the tissue118.

1.4.3

The link between IVD degeneration and pain

Despite the clinical association between radiographic IVD degeneration and LBP, this link
remains poorly understood. In fact, patients presenting with back pain often lack
radiographic signs of IVD degeneration, and many individuals with radiographic IVD
degeneration are completely asymptomatic124,125. While the difference between
symptomatic and asymptomatic IVD degeneration is not well understood, it has been
suggested that nerve in-growth may cause discogenic back pain126–128. During IVD
degeneration, both NP and AF cells release pro-nociceptive factors including IL-1, IL-6,
TNFα, and NGF108,129,130, which can act as nociceptive triggers. In addition to nerve
ingrowth to the disc and direct activation of nociceptors, it is believed that IVD
degeneration contributes to LBP in indirect mechanisms as well128. With IVD degeneration
there are structural and function changes within the IVD that impact adjacent tissues and
may provoke pain indirectly128. For example, in advanced IVD degeneration the significant
loss of IVD height can cause foraminal or central stenosis leading to compression of the
nerve roots or spinal cord128. Functional failure of the IVD may also lead to motion segment
instability43 leading to compensation from surrounding tissues128. This functional
compensation can lead to muscle strain/spasm, or degeneration of other tissues in the spine
such as the facet joint, which may also contribute to pain directly128,131.
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1.4.4

Treatment for IVD degeneration

There are no treatments to modify or prevent the progression of IVD degeneration. Current
therapeutic options address the primary clinical concern with IVD degeneration – back
pain - using lifestyle, pharmacological, and surgical interventions132. Recent clinical
guidelines suggest non-pharmacological therapies such as exercise and cognitive
behavioral therapy as first-line treatments, with limited pharmacological and surgical
interventions132. Despite these recommendations, surgical interventions (i.e. spinal fusions)
for chronic LBP is on the rise despite a lack of evidence of effectiveness132,133. The current
lack of disease-modifying treatments for IVD degeneration and associated LBP is largely
due to an incomplete understanding of the pathophysiology of the disease, and the interplay
between the tissues involved.

1.5

Similarities between IVD degeneration and osteoarthritis

The IVD shares several similarities with articular cartilage, and many of the pathways
associated with disc degeneration (detailed above) have also been implicated in the
pathogenesis of osteoarthritis (OA)134. OA is a heterogeneous disease that can affect
multiple joints – most commonly the knee - resulting in pain and loss of function in
patients 135,136. It is characterized by a progressive loss of articular cartilage, subchondral
bone sclerosis and synovial hyperplasia137. Clinically, OA is typically diagnosed based on
radiographic evidence of joint space narrowing, osteophyte formation, and sclerosis138.
Interestingly, these OA features are also detected in IVD degeneration139, which has
driven speculation about a potential link between the two pathologies. At the cellular
level, NP cells resemble articular chondrocytes and produce a similar ECM rich in type II
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collagen and aggrecan, while AF cells resemble those of the fibrous connective tissue
comprising of the articular joint capsule134. Similarities exist between the degenerative
processes in IVD degeneration and OA including alterations to the ECM, biomechanics,
genetic factors, inflammation, symptoms and risk factors, as recently reviewed134.
Despite these similarities, it should not be supposed that OA and IVD degeneration are
identical. There are differences in both the developmental origins and biomechanical
properties of each tissue. The IVD is formed by two different structures during
development, the notochord and sclerotome140,141. The notochord serves as the embryonic
precursor to the NP141, while the sclerotome contributes to the AF and adjacent vertebral
bones140. In contrast, the articular joints of the appendicular skeleton are formed later in
development, through the condensation of mesenchymal precursor cells142. While there
are key similarities between these two disease states, each involves distinct tissue types
and may differ in potential pathogenic pathways.

1.6

Mechanobiology of the IVD

In order for humans to remain upright, muscles of the posterior trunk contract and exert
high levels of mechanical load, especially in the lumbar spine143. As the “shock absorber”
of the spine, cells within the IVD are exposed to a variety of different loading modalities
such as compressive and tensile load143. Mechanical loading is a key regulator of IVD
homeostasis; multiple studies have highlighted the complexity of the cellular and molecular
events that it triggers in IVD cells (as reviewed in143). The effects of mechanical loading
on IVD cell physiology are dependent on both cell type and the loading parameters applied
(including load type, magnitude, frequency and duration). Several reviews have recently
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described the biological response of NP and AF cells to various mechanical loads47,98,143,144.
This body of work describes the physiological zone in which loading promotes matrix
synthesis and growth factor secretion to maintain disc health98. Outside of this zone –
either underloading or overloading - the cellular response shifts towards catabolism,
marked by the induction of matrix-degrading enzymes, inflammatory cytokines, and cell
apoptosis98.

1.6.1

Mechanical loads seen by the IVD

Different compartments of the IVD experience different parameters of mechanical load
and respond to these loads through different mechanisms. Due to overall anatomy of the
spine and surrounding musculature and ligaments, IVDs are never completely unloaded.
Instead, IVDs experience a constant level of mechanical stimulation known as preload59.
In addition to this preload, daily activity such as walking or lifting exerts additional
mechanical forces on the spine that are dissipated by the IVD143. In response to mechanical
loading, the osmotic properties of the NP enable to absorb compressive loads on the spine.
The consequent intradiscal pressure exerted by the NP is then dissipated by the tension that
develops between the lamellae of the AF81.

1.6.2

Mechanotransduction

The process by which cells sense mechanical stress and convert it into downstream
biological activity is known as mechanotransduction. Mechanotransduction occurs in three
coupled, yet distinct, steps: first, the mechanical stimulus is sensed by mechanoreceptors;
second, these receptors activate signal transduction pathways; and third, these pathways
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induce a cellular response145. While mechanotransduction pathways are not fully defined
in the IVD, several targets including integrins, purinergic receptors, and transient receptor
potential vanilloid 4 (TRPV4) ion channels have been implicated in the response of NP
and AF cells to mechanical loading146.

1.6.3

IVD tissue response to aberrant mechanical loads

While mechanical loading is essential for IVD health, overloading or underloading can
lead to catabolic processes associated with IVD degeneration98. Underloading of the spine
is experienced during prolonged immobilization or in zero gravity and has been shown to
accelerate IVD degeneration147,148. On the opposite end of the spectrum is overloading,
experienced for example during weightlifting or whole-body vibration, which likewise has
been shown to induce IVD degeneration147. In vitro, exposure to aberrant mechanical
loading induces the expression of matrix-degrading enzymes, inflammatory cytokines, and
cell apoptosis in both NP and AF cells98.

1.6.3.1

Whole-body vibration

Occupational exposure to high-amplitude, low-frequency whole-body vibration - typically
created by the operation of heavy equipment – has been shown to contribute to the
development of IVD degeneration and back pain149. Despite this, whole-body vibration
(WBV) platforms designed to deliver low-amplitude, high frequency mechanical vibration
are being used clinically based on their reported ability to increase bone density150 and
muscle strength151. Within the last decade, WBV has been integrated into physical therapy
regimens for a variety of musculoskeletal (MSK) disorders, including osteoporosis150, back
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pain152, and OA153. In addition to their clinical use, WBV platforms are marketed by the
health and wellness industry as “no-workouts” to replace traditional resistance training.
However, a dichotomy exists surrounding the safety of WBV: WBV is being promoted as
a safe and effective treatment for MSK conditions, yet epidemiological studies have
established a strong association between workplace exposure to WBV and the development
of MSK conditions

149

. Recognizing the potential of WBV to cause tissue damage, the

International Organization for Standardization (ISO) implemented guidelines indicating
the maximum daily limit workers can be exposed to WBV without being at risk for
injury154. However, there are no regulation associated with use of commercially available
WBV platforms, which are typically able to deliver vibration far greater than what ISO2631 guidelines deem as acceptable155.
Raising further concern, clinical trials have shown conflicting reports regarding the ability
of WBV to slow bone loss, and its effectiveness in reducing back and OA-associated pain.
In young women (15-20 years old) with low bone mineral density (BMD) daily WBV
therapy increased cortical BMD in the femoral mid-shaft156; however, the same researchers
subsequently reported that older males and females (mean age = 82) showed no significant
differences in BMD following exposure to WBV157. Clinical trials investigating the
effectiveness of WBV to treat back pain reported improvements in patient self-reported
pain158,159; however, these studies did not directly assess joint health. Based on the lack of
rigorous research-based evidence, a recent analysis cautioned against the use of WBV to
treat back pain152. Clinical trials evaluating the effectiveness of WBV for the treatment of
joint pain in knee OA have also shown conflicting results. A number of studies reported
that WBV reduced pain intensity153,160, while other studies report no significant
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improvement in pain intensity in knee OA patients following WBV161. The lack of rigorous
evidence-based research surrounding the efficacy and safety of WBV is concerning given
their prevalent use in physiotherapy clinics and gyms.
Given this conflicting evidence, our group carried out several studies using the mouse as a
preclinical model to directly assess the effects of WBV on skeletal health. These studies
demonstrated that exposure of mice to WBV using vibrational parameters used clinically
induces significant IVD degeneration and OA-like damage to the knee in as little as 4weeks162–164. In addition to gross histological damage, WBV induced inflammation within
the IVD marked by upregulation of Il-1β followed by upregulation of matrix degrading
enzymes associated with IVD degeneration including Mmp-3,-13 and Adamts5165. These
findings highlight the need for more comprehensive studies investigating the effects of
WBV on joint health.

1.7

Metabolism of the IVD

As the largest avascular tissue in the human body, the IVD has a unique metabolic profile
compared to other tissues. Aside from the outermost lamellae of the AF, the majority of
the nutrients are supplied to the IVD through diffusion from the CEPs67. As such, several
factors including blood supply to the adjacent tissues, loading and matrix composition
affect nutrient supply to the IVD

67

. The IVD has low cellularity and an extensive ECM

that impacts nutrient transport. The major components of this matrix are collagen fibers
and negatively charged proteoglycans that act as semi-permeable barrier to molecules
entering the disc. While small molecules such as oxygen and glucose are able to diffuse
through, the ECM limits the movement of large molecules such as growth factors and
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cytokines67,166. As a result of cellular metabolism and limits of diffusion, large
concentration gradients of oxygen, glucose and lactic acid are observed within the IVD67.
The center of the NP is an oxygen and glucose poor environment, with high levels of lactic
acid67,167.

The main source of ATP for AF and NP cells is through anerobic

glycolysis168,169, allowing NP cells to survive up to 13 days in the absence of oxygen170,171.
While the role of glucose and glycolytic production of ATP has been well characterized in
the IVD, the role of lipid metabolism in IVD homeostasis is unknown. Of note, mediators
of lipid metabolism impact articular cartilage health both negatively and positively, and
have been shown to alter the progression of OA172,173.

1.8

Animal models of IVD degeneration and back pain

As with many other MSK diseases, animal models are often used to understand the
pathophysiology of IVD degeneration and associated back pain174. A range of animal
models are used to study IVD degeneration, from large animals (e.g. sheep, goats) to small
rodents, that each have unique strengths and weaknesses. A common criticism of basic
spine research is the use of quadrupedal animals. It is often assumed that humans
experience higher mechanical loading on their IVDs due to upright posture. However,
muscular contraction is the major contributor to axial compression along the spine and
quadrupedal animals in fact experience higher relative compressive loading on their spines
compared to bipedal animals174–176. Spinal tissues from large animal models such as sheep,
and goats have a similar size, anatomy, mechanical loading and cellularity to those from
humans175, and have been used extensively for models of surgically-induced IVD
degeneration175. Despite these advantages, cost and associated limitations to sample size
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in experiments is a major deterrent for research involving large animals177. Most basic
research investigating IVD degeneration use small animal models. Rodents are most
frequently used based on their ease of use, low cost and the ability to manipulate their
genome174. Despite the size difference between human and mouse IVDs, both species have
similar geometry, biomechanics and extracellular matrix composition178–180. Aside from
their low housing costs and short generational times, one of the largest advantages of mouse
models is the relative ease of genetic manipulation. Use of the Cre/LoxP recombinase
system allows for modification of the murine genome in either a global or tissue specific
manner181–183. A number of studies using genetically modified mice have highlighted the
importance of matricellular and ECM components including CCN2, SPARC, and collagen
type IX in IVD degeneration and back pain184–186.
In addition to genetic manipulation, mouse models have been used extensively for pain
research187. Given the discordance between IVD degeneration and back pain, it is important
to simultaneously assess both in preclinical models of disease188. While pain is a complex
phenomenon, and limitations of mouse models should be acknowledged, their use has
provided a number of promising therapeutic targets for the treatment of chronic pain189. To
assess pain, several behavioral metrics have been developed for various modalities of
pain187,188. Generally, these tests assess for behavioral indicators of evoked or spontaneous
pain and are used extensively in the pain field187. In addition to behavioral metrics, mouse
models also allow for the assessment of biological indicators associated with pain, such as
neuroinflammation190. The use of animal models has provided researchers with valuable
knowledge about potential mechanisms contributing to IVD degeneration and LBP and
may potentially yield future therapeutic targets.
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1.9

Obesity

Obesity – traditionally defined as a body mass index over 30 – is a worldwide epidemic.
Obesity substantially increases the risk of developing metabolic, cardiovascular,
neurological and MSK diseases191. With the prevalence of obesity nearly tripling over the
last 30 years191, it poses a large public health concern. In the US, it is estimated that 21%
of the total healthcare expenditure is used to directly treat obesity and obesity-related
comorbidities192. At the individual level, obesity not only decreases life expectancy193 but
also decreases quality of life and leads to disability, mental illness and
unemployment191,194.

1.9.1

Metabolic syndrome

Although several factors contribute to obesity including hormonal, nutritional,
psychological and metabolic factors, obesity is fundamentally caused by an imbalance in
energy input and expenditure191,195 resulting in an accumulation of adipose tissue.
Evolutionarily, the ability to store energy for long periods of time was essential for
survival. However, in today’s industrial world where food is abundant and lifestyles are
sedentary, fat accumulation has negative health implications. As mentioned previously,
obesity – or more specifically the accumulation of abdominal fat – is related to the
development of several metabolic diseases, together termed metabolic syndrome196.
Components of metabolic syndrome include abdominal obesity/large waist circumference,
type II diabetes mellitus, hypertension, and dyslipidemia191,196,197. Together, these
conditions have a tremendous impact on overall systemic health, and increase the risk of
developing cardiovascular198, renal199 and MSK200 pathologies. Although the pathogenesis
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of metabolic syndrome is complex, abdominal obesity appears to be a key causative
factor201. Adipose tissue not only stores and releases fatty acids, but is also is a major
endocrine organ that synthesizes and secretes proteins and hormones termed adipokines
(e.g. leptin, adiponectin, visfatin, resistin) and inflammatory cytokines (e.g. TNF-α, IL6)202,203. Increased release of these molecules is associated with the development of many
aspects of metabolic syndrome including insulin sensitivity, hypertension and dyslipidemia
independently204,205. However, this link between obesity and metabolic syndrome appears
to be multifactorial, as increased adiposity is also associated with increase plasma levels of
free fatty acids (FFAs), which can independently contribute to insulin sensitivity,
hypertension and dyslipidemia206.

1.9.2

Musculoskeletal health

Obesity impacts several MSK tissues, including muscle, bone, and cartilage. Clinically,
obesity is associated with an increased risk of sarcopenia, osteoporosis, OA, LBP and IVD
degeneration207,208. While the mechanisms underlying these associations are not fully
elucidated, obesity and obesity-associated diseases likely contribute through direct actions
on the tissue of interest, as well as indirectly through effects on supporting tissues. A recent
review by Zhuo et al200 highlighted the differential impact of each component of metabolic
syndrome in the context of OA. A common indirect mechanism believed to impact joint
health is cardiovascular complications – postulated to lead to subchondral bone ischemia
and impaired nutrition of the joint. Hypertension162, dyslipidemia79,209 and type II
diabetes210,211

can lead to microvascular narrowing, atherosclerosis and endothelial

dysfunction79,209,210, potentially resulting in subchondral bone ischemia. Lack of blood
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supply

could

compromise

nutrient

exchange

ultimately

leading

to

cartilage

degeneration200,212. In humans, hypertension, dyslipidemia, and type II diabetes are also
independently associated with increased risk of IVD degeneration213–215. While the exact
mechanisms have not been determined, impaired nutrient exchange has been implicated as
a mediator of IVD degeneration67, and may be caused by these conditions. Aside from
these indirect effects, components of metabolic syndrome may impact joint health directly
through abnormalities in lipid/glucose metabolism and release of systemic factors200,216.
Dyslipidemia may contribute to IVD degeneration through alterations in the lipid
metabolism pathway. In chondrocytes, lipid metabolism regulates viability, matrix
synthesis and inflammation217. While the role of lipid metabolism in the IVD is not well
characterized, dysregulation of metabolic pathways in hypertriglyceridemia is associated
with IVD degeneration, caused by IVD cell apoptosis and matrix catabolism214.
Hyperglycemia resulting from type II diabetes is thought to contribute to IVD degeneration
through increased production of reactive oxygen species (ROS) and advanced glycation
end products (AGEs)200. In vitro, hyperglycemic conditions induce ROS production in both
articular chondrocytes218 and NP cells219, leading to matrix degeneration and apoptosis in
both tissues219,220. AGEs are products of non-enzymatic glycation of proteins that
accumulate with uncontrolled hyperglycemia221. In humans, AGEs accumulate in IVDs of
people with type II diabetes222, which is thought to contribute to IVD degeneration through
increased protein crosslinking, causing increased mechanical stiffness of the IVD223.
Supporting this, dietary consumption of AGEs in mice was associated with increased IVD
degeneration and altered biomechanics of spinal motion segments224. While biomechanical
changes may play a role in AGE-induced IVD degeneration, AGEs may also activate the
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receptor for advanced glycation end products (RAGE), which has been found to activate
pro-inflammatory and catabolic processes in chondrocytic cells225,226.
Studies investigating the role of adipokines have also highlighted the importance of
secreted factors in obesity-associated pathologies. For example, leptin-deficient mice
become obese, yet they do not develop knee OA, suggesting leptin may play a key role in
obesity-induced OA227. In the IVD, exposure of NP cells to adipokines, such as leptin and
resistin, promotes catabolic metabolism associated with increased expression of matrix
remodeling enzymes such as MMP and ADAMTS genes228,229.

1.9.3

Pain

In addition to the induction of degenerative joint diseases, obesity is also associated with
chronic pain conditions, such as fibromyalgia, headaches and abdominal pain230. While the
underlying mechanisms linking obesity and chronic pain remains unknown, it has been
suggested that systemic immune and endocrine alterations play a role in the altered pain
response231. Obesity is considered a low-grade chronic systemic inflammatory state with
elevated levels of IL-6 and C-reactive protein (CRP) that may contribute to pain231,232. Pain
is a biopsychosocial phenomenon4, so, in addition to these biological factors, obesity is
also associated with depression233 and poor sleep quality234. These conditions are both
known to contribute to pain through various mechanisms235,236. A summary of the proposed
mechanisms linking obesity with IVD degeneration and associated pain can be seen in
Figure 1.3.
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Figure 1.3: Proposed mechanism underlying the association between obesity/
metabolic syndrome, IVD degeneration, and pain.
The link between obesity, IVD degeneration and back pain is multifactorial, involving both
direct effects on the IVD and indirect effects on the nervous system and other tissues.
Obesity may directly contribute to structural IVD degeneration through increased
mechanical loading, systemic inflammation and adipokine signaling. Metabolic
dysregulation associated with obesity leading to diabetes, hypertension and dyslipidemia
may compound these direct effects and potentiate further degeneration. Indirectly, obesity
and obesity-related pathologies may also alter pain-processing pathways contributing to
back pain. Furthermore, damage/dysfunction of adjacent tissues (i.e. vasculature, muscle,
vertebral bone, facet joints) caused by obesity may lead to both structural IVD degeneration
and back pain. Figure based on content provided in199.
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1.10 Nuclear Receptors
1.10.1

Structure

Nuclear receptors are a large family of ligand-regulated transcription factors activated by
binding of steroid hormones, such as estrogen and progesterone, and lipid-soluble signals,
including retinoic acid, oxysterols, and thyroid hormone, to alter transcription of
downstream target genes237. Although nuclear receptors have different, and often opposing
actions, they share a common structure. All nuclear receptors contain 4 domains, including
the N-terminal domain that is of variable size and sequence, a conserved DNA binding
domain, a variable hinge domain, and a ligand binding domain 237. Some nuclear receptors
contain an activation function-1 (AF-1) domain at the N-terminal domain, which is a
ligand-independent domain that assists in the recruitment of coactivators238. The centrally
located DNA binding domain is the most conserved segment of nuclear receptors; it
contains two zinc fingers that binds to hormone response elements on the promoter of
downstream target genes239. The hinge domain connects the DNA binding domain to the
ligand-binding domain, which is a 12 helixed structure containing a ligand-dependent
activation-function 2 (AF-2) domain237. A major characteristic of the ligand binding
domain is a hydrophobic cavity that allows lipophilic ligands to be shielded from the
hydrophilic environment237. These pockets allow selectivity for specific ligands through
variations in size and amino-acid composition240. Binding of the ligand stabilizes the
surface elements of the ligand binding domain and allows for coactivator/corepressor
binding, altering downstream gene transcription237,241,242.
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Nuclear receptors are divided into 4 main classes. Class I nuclear receptors are normally
located in the cytoplasm bound to chaperone proteins, but through ligand activation are
translocated to the nucleus where they can bind DNA and affect gene transcription243. Class
I nuclear receptor ligands are steroid hormones such as estrogen, testosterone and
corticoids244. Class II nuclear receptors on the other hand, remain in the nucleus regardless
of ligand-activation243. Class II nuclear receptors are commonly found as heterodimers
with retinoid X receptor (RXR), and include Peroxisome Proliferator Activated Receptors
(PPARs), Liver X receptor (LXR), Farnesoid X receptor (FXR) and Vitamin D receptor
(VDR)245. Class III nuclear receptors are similar to class II, however they typically exist as
homodimers on their response elements243. Class IV nuclear receptors also have a similar
mechanism of action to class II nuclear receptors, but typically are found as monomers on
DNA243.
Many class II receptors respond to dietary lipids such as fatty acids (PPARs), sterols
(LXR), bile acid (FXR), serving as “lipid sensors”246. Activation of these receptors occurs
at physiological lipid concentrations influenced by dietary intake and leads to changes in
transcription of genes involved in lipid metabolism, storage, transport and elimination246.
While ligand binding is the major activator of nuclear receptors, their activity can also be
modulated by posttranslational modifications, including phosphorylation, ubiquitination,
and SUMOylation239.

1.10.2

Peroxisome Proliferator Activated Receptors (PPARs)

The PPARs are a subfamily of nuclear receptors whose ligands include fatty acids and their
metabolites, which are of interest as they are dysregulated in obesity200,247. As a type II
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nuclear receptor, PPARs form heterodimers with RXR, and when bound to their ligands
they recruit co-activators or co-repressors to either activate or repress downstream gene
expression depending on specific gene and cellular context243,248. There are three PPAR
isoforms (alpha, delta, gamma) that play distinct roles in energy balance and metabolism249.
The two most studied isoforms, PPARα and PPARγ, are highly expressed in the liver and
adipose, respectively. Agonists of these receptors are currently being used clinically for the
treatment of a variety of obesity-associated conditions including dyslipidemia and type II
diabetes mellitus250,251. Studies examining the role of PPARγ in murine cartilaginous
tissues have shown that a cartilage-specific knockout of PPARγ leads to spontaneous OA
development252. In contrast to the tissue-specific expression of other PPARs, PPARδ has
broad expression patterns and affects glucose and lipid metabolism, cell differentiation,
proliferation, apoptosis and immune regulation253. Recent studies in mice have shown
PPARδ agonism improves insulin resistance, fat burning, and muscle endurance247,254,255;
however, PPARδ agonism has also been shown to induce catabolic processes within
articular cartilage172,256. In a murine organ culture model, activation of PPARδ lead to
proteoglycan degradation in articular cartilage through increased expression of proteases
including Mmp-3 and Adamts-5172,256. Moreover, mice with cartilage-specific deletion of
PPARδ are protected from cartilage damage in a post-traumatic model of OA172. While
the biological mechanisms behind the role of PPARδ in articular cartilage are not fully
understood, it appears to contribute to the regulation of lipid metabolism and the cellular
response to oxidative stress256. Although the role of PPARs in the IVD have not been
directly investigated, PPAR expression is detected in both the NP and AF257. The
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similarities between articular cartilage and IVD biology and pathophysiology suggest that
PPARs may be intriguing candidates as potential regulators of IVD degeneration.

1.11 Overall objectives and hypothesis
Using the mouse as a preclinical model, this thesis focuses predominantly on examining
the role of two important environmental risk factors in the initiation and progression of
IVD degeneration and associated pain: mechanical loading and obesity.

1.11.1

Objective #1

Investigate whether the detrimental effects of WBV on joint health are altered by genetic
background in mouse models.

1.11.1.1

Rationale #1

Previous research by our group demonstrated that exposure of mice to protocols of WBV
that model those used clinically (30 minutes/day, 5 days/week; 45 Hz, 0.3 g) induced
damage to the IVD and knee joint within two weeks, that progressed in severity with
continued daily exposure to WBV (i.e. 4, 8 weeks)162,164,165. These studies were however
limited to skeletally mature (10-week old) male mice of a single outbred stock (CD1). Due
to the diverse human population using WBV platforms we aimed to determine whether the
response of joint tissues to WBV was consistent between mice of different genetic
backgrounds.
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1.11.1.2

Hypothesis # 1

The effects of whole-body vibration on joint health will differ based on genetic
background.

1.11.2

Objective #2

Determine whether chronic exposure of mice to a high-fat or high-fat/high-sugar western
diet will accelerate age-related IVD degeneration and/or back pain.

1.11.2.1

Rationale #2

Throughout the world, the prevalence of obesity is on the rise. In 2014 over 25% of
Canadians were obese, resulting in an enormous toll on our health care system of over $4
billion spent annually on direct costs alone, let alone costs associated with obesityassociated co-morbidities258. In addition to being a major risk factor for the development
of type II diabetes, cardiovascular disease and metabolic syndrome259, obesity also
increases the risk of IVD degeneration and lower back pain260,261. Despite this
association there is very little known about the pathogenesis of obesity induced IVD
degeneration. Previous research demonstrated that obesity induced by a high-fat diet
accelerates OA in mouse and rat models262–266. In addition to structural changes in the
joint, the high-fat diet also induces symptomatic characteristic of OA, such as
hyperalgesia263. To date, the effect of diet-induced obesity on IVD degeneration and back
pain has not been directly studied.
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1.11.2.2

Hypothesis # 2

Chronic consumption of a high-fat or high-fat/high-sugar western diet will accelerate
IVD degeneration and/or behavioral indicators of back pain in the mouse model.

1.11.3

Objective # 3

Determine the role of PPARδ in age- and obesity-associated IVD degeneration and
investigate sex as a variable in the mouse model system.

1.11.3.1

Rationale # 3

Based on previous research demonstrating that loss of PPARδ in articular cartilage
protects from surgically-induced and age-associated OA172,267 , we sought to determine
the role of PPARδ in the IVD and is contribution to both age- and obesity-associated IVD
degeneration and pain. Previous studies by our lab using genome-wide transcriptome
analysis demonstrated that many nuclear receptor pathways are activated in ageassociated IVD degeneration, including the PPAR signaling pathway257, highlighting the
potential importance of PPAR in age-associated IVD degeneration. Given that its
endogenous ligands are dysregulated in obesity247, and the detrimental role of PPARδ
activation in articular cartilage172, we aimed to determine whether similar findings would
be seen between the different models of IVD degeneration.
This study also sought to address potential sex-related differences in IVD degeneration
and back pain in our model of diet-induced disc degeneration. Numerous pre-clinical and
clinical studies have shown that IVD degeneration and back pain are sexually dimorphic,
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where females are disproportionately more affected by spinal pathologies and back pain
than males95,268.

1.11.3.2

Hypothesis # 3

Loss of PPARδ in IVD cells will delay the progression of age- and obesity-related IVD
degeneration and back pain.
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2

C57BL/6 mice are resistant to joint degeneration induced by
whole-body vibration.

2.1
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2.2

Chapter Summary

Objective: Whole-body vibration (WBV) platforms are commercially available devices
that are used clinically to treat numerous musculoskeletal conditions based on their
reported ability to increase bone mineral density and muscle strength. Despite widespread
use, there is an alarming lack of understanding of the direct effects of WBV on joint health.
Previous work by our lab demonstrated that repeated exposure to WBV using protocols
that model those used clinically, induces intervertebral disc (IVD) degeneration and
osteoarthritis-like damage in the knee of skeletally mature, male mice of a single outbred
strain (CD-1). The present study examined whether exposure to WBV induces similar
deleterious effects in a genetically different strain of mouse (C57BL/6).
Design: Male 10-week-old C57BL/6 mice were exposed to vertical sinusoidal WBV for
30 min/day, 5 days/ week, for 4 or 8 weeks using previously reported protocols (45 Hz, 0.3
g peak acceleration). Following WBV, joint tissues were examined using histological
analysis and gene expression was quantified using real-time PCR (qPCR).
Results: Our analyses show a lack of WBV-induced degeneration in either the knee or
IVDs of C57BL/6 mice exposed to WBV for 4 or 8 weeks, in direct contrast to the WBVinduced damage previously reported by our lab in CD-1 mice.
Conclusions: Together with previous studies from our group, the present study
demonstrates that the effects of WBV on joint tissues vary in a strain-specific manner.
These findings highlight the need to examine genetic or physiological differences that may
underlie susceptibility to the deleterious effects of WBV on joint tissues.
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2.3

Introduction

Platforms that deliver whole-body vibration (WBV) are currently used in the clinical
setting based on their reported ability to increase bone density1 and muscle strength2.
Within the last decade, WBV has been integrated into physical therapy regimens for a
variety of musculoskeletal disorders, including osteoporosis1, back pain3, and
osteoarthritis4. In addition to their clinical use, WBV platforms are promoted in the health
and wellness industries as “no-work workouts” equivalent to traditional resistance training.
The proposed use of WBV as a treatment for musculoskeletal conditions appears
contradictory to epidemiological studies establishing an association between workplace
exposure to WBV and the development of several conditions, including back pain5.
Recognizing the potential of WBV to induce tissue damage, the International Organization
for Standardization (ISO) implemented guidelines defining the maximum daily limit of
WBV that workers can be exposed to without risk for injury6. Conversely, commercially
available WBV platforms are currently unregulated, with some able to deliver accelerations
that exceed current ISO-2631 recommended guidelines7.
Raising further concern regarding the use of WBV, clinical trials show conflicting reports
regarding the ability of WBV to increase bone mineral density1,8. Similarly, clinical trials
investigating the effectiveness of WBV for knee or back pain have failed to show
conclusive evidence, with only a small proportion of trials showing benefits based on
assessments of patient self-reported pain3,9. A cause for concern is that the widespread use
of WBV has not been validated with rigorous research-based evidence addressing the broad
range of parameters used and potential harmful effects.
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Investigating the effects of WBV on joint tissues, our research has demonstrated that
exposure of mice to protocols of low-amplitude, high-frequency WBV that model those
used clinically induced intervertebral disc (IVD) degeneration and osteoarthritis-like
damage in the knee of skeletally mature, male mice, of a single outbred strain (CD-1)10–12.
Given these strikingly deleterious effects of WBV, the present study aimed to determine if
the response of joint tissues to WBV was consistent in age- and sex-matched C57BL/6
mice representing a distinct genetic background.

2.4
2.4.1

Methods
Whole body vibration

Based on WBV parameters used in clinical protocols and our previous studies10–12, 10week-old male C57BL/6 mice (Charles River) were subjected to vertical sinusoidal
vibration (45Hz, peak-to-peak amplitude 74 µm, peak acceleration 0.3 g) 30 minutes/day,
5 days/week for 4 or 8 weeks. Age- and sex-matched controls were housed in identical
chambers on a non-vibrating sham platform to replicate handling and environmental
conditions. Following WBV, mice were returned to conventional housing and monitored
daily. No differences in total body mass were detected between groups. Mice were
euthanized with sodium pentobarbital 24 hours after final exposure to WBV. The Council
on Animal Care at Western University approved all procedures, in accordance with the
Canadian Council on Animal Care and the ARRIVE guidelines.

65

2.4.2

Gene expression analysis

Thoracic IVDs (T10-T15) were isolated from mice exposed to 8 weeks WBV and sham
controls, placed in TRIzol (Life Technologies) and homogenized using a PRO250 tissue
homogenizer (PRO Scientific). RNA was extracted according to manufacturer's
instructions, quantified using a NanoDrop 2000 spectrophotometer (Thermo Scientific),
and 0.5 µg was reverse transcribed into complementary DNA (cDNA) (iScript; Bio-Rad).
Gene expression was assessed by real-time PCR (qPCR) using the Bio-Rad CFX384. PCR
analyses were run in triplicate using 120 ng of cDNA per reaction and 310 nM forward and
reverse primers with 2x SsoFast EvaGreen Supermix (Bio-Rad) using previously
optimized PCR parameters and primers11. Transcript levels were calculated using ΔΔCt,
with data normalized for input based on Ribosomal protein S29 (Rps29) and expressed
relative to non-vibrated sham controls.

2.4.3

Histological analysis

Intact lumbar spine segments (L1-L5) and knees were isolated, fixed and paraffin
embedded as previously described11. Spines were sectioned sagittally and knees were
sectioned coronally, at a thickness of 5 µm using a microtome (Leica Microsystems).
Spines sections were stained using 0.1% Safranin-O/0.05% fast green, and knee sections
were stained with 0.04% Toluidine Blue. Sections were imaged on a Leica DM1000
microscope, with Leica Application Suite (Leica Microsystems). To evaluate IVD
degeneration, mid-sagittal sections were scored using the modified Thompson grading
scheme to assess IVD health based on criteria specific to each tissue compartment (scores
1-4, where a lower score corresponds to a more healthy tissue), as previously reported10,11.
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Knee joint health was assessed using the murine Osteoarthritis Research Society
International (OARSI) histopathological scale13. For each mouse, the four quadrants of the
knee joint were evaluated in 10 serial sections taken 75 µm apart to include most of the
weight-bearing area of the femorotibial joint. For each quadrant of each section individual
scores were averaged between three independent blinded observers and summed across the
10 sections for each mouse. The whole joint score was calculated as the sum of the quadrant
scores for each mouse.

2.4.4

Statistical analysis

Data are from experiments conducted with n = 5-6 mice per group at each time point. For
qPCR analyses, data from mice exposed to WBV were compared to non-vibrated sham
controls using a parametric Welch’s t-test. At each time point, histopathological scores
from the IVD or knee joint were compared using a non-parametric Mann-Whitney U-test.
Differences were accepted as statistically significant at P < 0.05.

2.5

Results

To examine the effects of repeated exposure to WBV on joint health, 10-week-old
C57BL/6 mice were exposed to WBV for 30 min/day, 5 days/week for either 4 or 8 weeks,
using parameters that model clinical use in humans (45 Hz, 0.3 g)11. Importantly, these
parameters were previously found to induce degeneration of both the IVD and knee joint
in age- and sex-matched CD-1 mice, marked by histological hallmarks of tissue damage
including annulus fibrosus degeneration in the IVD as well as meniscal damage and focal
defects in the articular surface of the knee10–12. In the C57BL/6 mice, we first assessed
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IVD health. No discernable differences were detected in the histological appearance of
lumbar IVDs in mice exposed to 4 or 8 weeks of WBV compared to their respective sham
controls (Figure 2.1A). Accordingly, evaluation of IVD structure using the modified
Thompson score showed no significant differences in degeneration grade between mice
exposed to 4 or 8 weeks of WBV and their respective sham controls (Figure 2.1B). As a
more sensitive measure of early degenerative changes in IVD tissues, we evaluated the
cellular response to WBV using real-time PCR. Similar to histological evaluation, this
analysis revealed no change in the expression of anabolic (Acan, Col1a1, Col2a1, Sox9) or
catabolic (Mmp3, Mmp13, Adamts4, Adamts5) factors between mice exposed to 8 weeks
of WBV and non-vibrated sham controls (Figure 2-1C).
We then assessed if exposure of C57BL/6 mice to WBV induced changes to knee joint
tissues. Consistent with findings in the IVD, no discernable differences were detected in
the knee joint of C57BL/6 mice exposed to 4 or 8 weeks of WBV compared to their
respective sham controls (Figure 2-2A). In contrast to our previous studies in CD-1 mice10,
exposure of C57BL/6 mice to WBV did not induce any observable meniscal damage,
articular cartilage erosion or osteophyte formation. Evaluation of cartilage degeneration
using the OARSI histopathological score supported these observations; no significant
differences were found in the summed OARSI score between mice exposed to WBV and
sham controls (Figure 2-2B).
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Figure 2.1: Effect of repeated exposure to WBV on IVD health.
A. Representative sagittal sections of the lumbar spine stained with safranin-O/fast green
from mice exposed to WBV (for 4 or 8 weeks, 30 minutes per day, 5 days per week, at 45
Hz and 0.3 g) and non-vibrated sham controls. Images are oriented with rostral portion of
the lumbar spine on top and dorsal portion on the left. B. Histopathological scores
generated using the modified Thompson grading scale demonstrated no significant
differences in degeneration score corresponding to the annulus fibrosus (AF) or nucleus
pulposus (NP) from mice exposed to either 4 or 8 weeks WBV compared to their respective
non-vibrated sham controls. C. Real-time PCR analysis of IVD gene expression in mice
exposed to 8 weeks WBV and sham controls. Expression of extracellular matrix genes
(Acan, Col1a1, Col2a1), the transcription Sox9, and matrix remodeling enzymes (Mmp3,
Mmp13, Adamts4, Adamts5) were determined relative to the expression of the
housekeeping gene Rps29 and normalized to that of non-vibrated sham controls. Data are
presented as mean ± 95% CI (n = 5-6 mice per group).
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Figure 2.2: Effect of repeated exposure to WBV on knee health.
A. Representative coronal sections of the medial knee compartment stained with toluidine
blue from mice exposed to WBV (30 minutes per day, 5 days per week, for 4 or 8 weeks
at 45 Hz and 0.3 g) and non-vibrated sham control mice. Images are oriented with the
medial femoral condyle located superiorly, and the medial tibial plateau inferiorly. B.
Histopathological grading of the knee joints using the murine Osteoarthritis Research
Society International (OARSI) scale. Joints from each mouse were evaluated using 10
serial sections (taken 75 µm apart) and the summed OARSI scores are presented
corresponding to the medial femoral condyle (MFC), medial tibial plateau (MTP), lateral
femoral condyle (LFC) and lateral tibial plateau (LTP), which were then combined to
generate the summed score for the whole joint (WJ). No significant differences in
degeneration scores were detected between mice exposed to WBV and sham controls in
any of the compartments investigated. Data are presented as mean ±95% CI (n = 5-6 mice
per group).
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2.6

Discussion

Despite the widespread clinical and recreational use of WBV platforms, there is an
alarming lack of understanding of the effects of WBV on overall joint health as well as the
effects elicited in specific joint tissues. Previous studies from our group demonstrated the
ability of WBV to induce IVD degeneration and osteoarthritis-like damage in the knee of
skeletally mature male outbred CD-1 mice11. After 4 weeks of repeated exposure to WBV,
CD-1 mice showed degeneration in the annulus fibrosus of the IVD, marked by disruption
of collagen organization, enhanced MMP-mediated collagen and aggrecan degradation,
and increased cell death. Similarly, 4 of 5 CD-1 mice exposed to WBV for 4 weeks showed
meniscal damage, and 2 of 5 showed focal damage to the articular cartilage associated with
increased MMP-mediated matrix degradation11. Subsequent studies from our group
showed that WBV-induced damage to both the IVD and knee joint increased in severity
when CD-1 mice were exposed to 8 weeks WBV10,12. In direct contrast, the current study
demonstrates that exposure of C57BL/6 mice to those same parameters of WBV did not
induce degeneration-associated changes in either the knee or IVD after 4 or 8 weeks of
exposure. Thus, the effects of WBV on joint tissues differ between different strains of mice,
highlighting the need to examine factors that may determine susceptibility to the
deleterious effects of mechanical loading on joint health.
Previous work has reported strain-specific differences in the attenuation of vibration
loading in rodent models, as well as its downstream consequences on bone parameters14,15.
Studies investigating vibration frequency thresholds in rodents reported that the resonant
frequency range differs between strains of mice14. At the resonant frequency, it is assumed
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that there is maximal displacement and consequently strain experienced by skeletal
structures, whereas frequencies outside of this range of vibration are attenuated by the
body14. When anesthetized mice were exposed to vibration frequencies ranging from 0600 Hz (at a constant magnitude of 0.3 m/s2), C57BL/6 mice showed the least amount of
attenuation between 41-50 Hz, whereas CD-1 mice showed the least amount of attenuation
between 51-60 Hz, suggesting difference in their resonant frequency ranges14. While the
biological factors underlying these differences were not explored, it has been suggested
that differences in baseline bone parameters between mouse strains may alter the
mechanical forces experienced at the tissue level15. Studies investigating the response of
trabecular bone to whole-body vibration (45 Hz, 0.25 g; 10 min/day, 3 weeks)
demonstrated that low bone mineral density C57BL/6 mice showed significantly higher
bone formation rates induced by WBV compared to mid-density BALB/cByJ mice15.
Moreover, C3H/HeJ mice which showed the highest bone mineral density, showed no
changes in bone formation rates following exposure to the same parameters of WBV15.
Clinical trials in humans report that women with lower body mass showed a greater
inhibition of bone loss when exposed to WBV compared to women with higher body mass;
since bone mineral density is positively correlated with body mass the authors suggested
that women with low bone mineral density may be most responsive to mechanical loading
to prevent bone loss1. Attenuation of vibration may depend on bone density and other
physiological factors including activity levels, body mass or joint structure, may alter the
mechanical loading experienced at the tissue or cellular level, and potentially contribute to
the differential response of joint tissues to WBV that we have shown between the CD-1
and C57BL/6 strains. Of note, the C57BL/6 mice used in the current study had an average
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mass of 26 g at 18 weeks of age, compared to the CD-1 mice used in the previous study
which had an average mass of 41 g at 18 weeks of age. Further studies are required to
assess the relative contribution of biological mediators that might underlie the differences
in the effects of WBV on joint tissues in different strains of mice, allowing for potential
extrapolation to the clinical setting.
In summary, this study showed that repeated exposure of skeletally mature male C57BL/6
mice to WBV for 4 or 8 weeks did not alter overall health of the IVD and knee joints; in
direct contrast to the WBV-induced joint degeneration we previously reported in CD-1
mice of the same age and sex. Although the results of the current study suggest that
C57BL/6 mice are resistant to WBV-induced damage, it should be noted that different
frequencies and accelerations may lead to differential responses. Previous studies in
musculoskeletal tissues established that mechanical loading can induce both catabolic and
anabolic responses, dependent on the load type, frequency, amplitude and exposure time16.
Previous research by our group has shown the potential of WBV to induce anabolic effects
in the IVD after acute exposure17. Together, these findings highlight the need for more
rigorous investigations to examine the efficacy and safety of WBV in the diverse human
populations currently using them, with emphasis on quantifying potential beneficial or
detrimental effects on musculoskeletal tissues.
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Chapter 3

Diet-induced obesity leads to behavioral indicators of pain preceding structural joint
degeneration in wild-type mice.

Chapter 3 is authored by Kerr, G.J, To, B., White, I., Millecamps, M., Beier, F., Stone,
L.S., and Séguin, C.A. and is entitled “Diet-induced obesity leads to behavioral indicators
of pain preceding structural joint damage in wild-type mice”. This study is in preparation
for submission.
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3

Diet-induced obesity leads to behavioral indicators of pain
preceding structural joint degeneration in wild-type mice.

3.1
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3.2

Chapter Summary

Introduction: Obesity is one of the largest modifiable risk factors for the development of
musculoskeletal diseases, including intervertebral disc (IVD) degeneration and back
pain. Despite the clinical association, no studies have directly assessed whether dietinduced obesity accelerates IVD degeneration, back pain, or investigated the biological
mediators underlying this association. In this study we examine the effects of chronic
consumption of a high-fat or high-fat/high-sugar (western) diet on the IVD and painassociated outcomes.
Methods: Male C57BL/6N mice were randomized into one of three diet groups (chow
control; high-fat; high-fat, high-sugar western diet) at 10-weeks of age and remained on
the diet for 12, 24 or 40 weeks. At endpoint, animals were assessed for behavioral
indicators of pain, joint tissues were collected for histological and molecular analysis, and
IBA-1, GFAP and CGRP were measured in spinal cords by immunohistochemistry .
Results: Animals fed obesogenic (high-fat or western) diets showed behavioral indicators
of pain beginning at 12 weeks and persisting up to 40 weeks of diet consumption.
Histological indicators of joint degeneration were not detected in the IVD or knee until 40
weeks on the experimental diets. Mice fed the obesogenic diets showed increased
intradiscal expression of inflammatory cytokines and circulating levels of MCP-1
compared to control. Linear regression modeling demonstrated that age and diet were both
significant predictors of most pain-related behavioral outcomes, but not histopathological
joint degeneration.
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Conclusion: Diet-induced obesity accelerates IVD degeneration and knee OA in mice;
however, pain-related behaviors precede and are independent of histopathological
structural damage. These findings contribute to understanding the source of obesityrelated back pain and the contribution of structural IVD degeneration.

3.3

Introduction

Obesity – traditionally defined as a body mass index over 30 – is a worldwide epidemic.
Obesity substantially increases the risk of developing metabolic, cardiovascular,
neurological and musculoskeletal diseases1, and with the prevalence nearly tripling over
the last 30 years1, it poses a large public health concern. Obesity decreases both life
expectancy2 and quality of life, and is associated with increased disability, mental illness
and unemployment1,3. A significant contributor to obesity-induced disability is low back
pain (LBP)

4,5

, which is the single most common cause of long-term pain and disability

worldwide6. Despite efforts to improve the clinical management of LBP, treatments are
limited to symptomatic relief, often without treating the underlying cause of the pain7. This
is largely due to an incomplete understanding of the tissues and pathways involved in the
initiation and progression of LBP. While several tissues appear to be involved in LBP,
including the paraspinal muscles, ligaments, and facet joints8–10, degeneration of the
fibrocartilaginous intervertebral disc (IVD) is believed to be the major contributor to pain
in an approximately 40% of cases8.
Despite the clinical associations between LBP, IVD degeneration, and obesity, the
underlying mechanisms and biological pathways responsible remain unknown. One
contributing factor appears to be increased mechanical loading. Excess weight alters the
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mechanical load experienced by the IVD11, a known regulator of IVD cellular function12,13.
Increased body weight is associated with indices of lumbar disc degeneration including
disc space narrowing and decreased lumbar disc signal intensity detected by MRI14,15. In
articular cartilage, excess weight and altered mechanical loading has also been suggested
to contribute to osteoarthritis (OA)16, a degenerative musculoskeletal disease with many
similarities to IVD degeneration17. Of note, increased mechanical load alone does not
account for the association between obesity and OA, as obese individuals also present more
frequently with OA in non-weight bearing joints, such as the hand18.
In addition to increased mechanical load, metabolic abnormalities associated with obesity
impact musculoskeletal health19,20. Obesity is associated with chronic metabolic disorders
including hypertension, diabetes mellitus and dyslipidemia, collectively known as
metabolic syndrome21. In the context of OA, it is postulated that each component of
metabolic syndrome may independently contribute to disease progression, as
comprehensively reviewed by Zhuo et al.22 Specifically, alterations in the release of
systemic factors (inflammatory cytokines, adipokines), nutrient exchange, advanced
glycation end-products (AGEs) levels and glucose/lipid metabolism are believed to be
major contributors to OA progression19,22. Studies from multiple groups have demonstrated
using mouse models that obesity induced by a high-fat diet accelerates the progression of
both age- and surgically-induced knee OA23–27, accompanied by behavioral indicators of
pain23. Aside from its role in energy storage, adipose tissue is also a major endocrine organ
and has been shown to secrete hormones termed adipokines (e.g. leptin, adiponectin,
visfatin, resistin) and inflammatory cytokines (e.g. TNF-α, IL-6, TGF-β)28. Studies
investigating the role of adipokines have highlighted their importance in obesity-associated
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pathologies. For example, leptin-deficient mice become obese yet they do not develop knee
OA, suggesting leptin may play a key role in obesity-induced OA29. In the IVD, exposure
of NP cells to adipokines, such as leptin and resistin, promotes catabolic metabolism
associated with increased expression of matrix remodeling enzymes such as MMP and
ADAMTS genes30,31. Adipokines also appear to play a role systemically as modulators of
pain sensitivity32. In addition to back pain, obese individuals are more likely to develop
chronic pain conditions such as fibromyalgia, headaches and abdominal pain33. While the
underlying mechanisms linking obesity and chronic pain remains unknown, it has been
suggested that systemic immune and endocrine alterations play a role in the altered pain
response34. This systemic modulation of pain may contribute to LBP in addition to
structural alterations and local inflammation within the IVD itself.
While there is extensive clinical evidence supporting the association between obesity, LBP
and IVD degeneration35,36, no studies have directly assessed whether diet-induced obesity
accelerates IVD degeneration, back pain, or investigated biological mediators underlying
this association. The current study was designed to investigate whether chronic
consumption of a high-fat or high-fat, high-sugar western diet alters the progression of agerelated IVD degeneration or back pain using the mouse as a model.

3.4
3.4.1

Methods
Mice and Diets

Wild-type, male, C57BL/6N (Charles River: Wilmington, MA, USA) mice were used.
Mice were fed standard chow (Envigo 2018) after weaning and randomized at 10-weeks
of age into one of three diet groups (n=9-16 mice/group; Table 3.3, Supplementary Table
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1) based on previous reports of obesity and metabolic derangement in mice26,37: high-fat
diet (60% kcal fat, 21% kcal carbohydrate; Envigo TD.06414), western diet (45% kcal fat,
41% kcal carbohydrate; Envigo TD.10885), or standard chow (18% kcal fat, 58% kcal
carbohydrate). Mice remained on the experimental diets until sacrifice at 5, 8 or 11.5
months-of-age (12-, 24-, 40-weeks on diet, respectively). Mice were housed in standard
cages and maintained on a 12 hr light/dark cycle, with food and water consumed ad libitum;
food consumption and body weight were measured weekly. All aspects of this study were
conducted in accordance with the policies and guidelines set forth by the Canadian Council
on Animal Care and were approved by the Animal Use Subcommittee of the University of
Western Ontario (protocol 2017-154; Appendix B).

3.4.2

Characterization of pain-associated behavior

Behavioral analysis was conducted on mice following 12-, 24-, or 40-weeks on
experimental or control diets. Behavioral studies were preceded by a two-week habituation
to the neurobehavioral testing facility, and mice were habituated to all tests one week prior
to data collection. On data collection days, animals were habituated to the testing room for
1 h before test start. To avoid confounding variables associated with the diurnal cycle, all
behavioral assessments were conducted between 8 and 11 AM.

3.4.2.1

Stretch induced axial discomfort

Stretch-induced axial discomfort was measured using the tail suspension test and grip force
during axial stretch, as described previously38–40. For the tail suspension test, spontaneous
reaction to gravity-induced stretch was assessed in mice suspended by the base of their tails
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for 180 s. Two observers blinded to the experimental groups independently scored the
duration of time spent by mice in immobility, full extension, rearing, or self-supporting
using ANY-maze software (Stoelting Co.: Wood Dale, IL). Voluntary activity was
quantified for 5 min immediately before (pre) and after (post) tail suspension using open
field activity monitors (AccuScan Instruments, Omnitech Electronic: Columbus, OH), to
quantify movement-evoked discomfort. The difference in total distance between the two
open-field sessions (post - pre) was calculated for each mouse.
For the grip force assay, mice were positioned to grab onto a metal bar attached to a grip
force meter (Stoelting Co.: Wood Dale, IL), and then gently pulled back by their tails to
exert axial stretch. Tolerance was assessed by measuring the grip strength, in grams, for
each mouse at the point of release averaged over 3 trials.

3.4.2.2

Hind limb sensitivity to mechanical and cold stimuli

Mechanical sensitivity was measured through application of calibrated Von Frey filaments
(Stoelting Co.: Wood Dale, IL) to the plantar surface of the hind paw for 3 s or withdrawal.
50% withdrawal threshold was calculated using the Chaplan up-down method41.The
stimulus intensity ranged from 0.07-6.0 g, beginning with a stimulus intensity of 1.4 g.
Cold sensitivity was assessed by measuring the total time spent by mice in behavior evoked
by evaporative cooling of acetone (flicking, stamping or licking of ventral surface of the
paw) during the first 40 s following application of 50 μL acetone to the ventral surface of
the hind paw. The test was carried out twice for each paw, with at least 5 min recovery
between each test. Times were then averaged between paws.
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3.4.2.3

Spontaneous activity

Voluntary locomotor activity was assessed using open field activity monitors (AccuScan
Instruments, Omnitech Electronic: Columbus, OH). Mice were placed into individual
boxes and their activity was monitored over 2 h. This was repeated for 3 consecutive days
and values were averaged for each mouse.

3.4.3

Micro-computed tomography (Micro-CT)

Forty-eight hours before sacrifice, µCT imaging was performed using a cone-beam
imaging system (eXplore SpeCZT scanner, GE Healthcare Biosciences: London, CAN).
For imaging, mice were anesthetized using 2-3% inhaled isoflurane (CA2L9100, Baxter:
Mississauga, CAN) infused with oxygen at a flow rate of 1.0 mL/min. To maintain
sedation, a nose cone apparatus was used to administer 1.75% inhaled isoflurane for 20
min while scanning was performed. During a single 5 min rotation of the gantry, 900 Xray projections were acquired (peak voltage of 90 kVp, peak tube current of 40 mA, and
integration time of 16 ms). A calibrating phantom composed of air, water, and cortical
bone-mimicking epoxy (SB3; Gammex, Middleton WI, USA) was included in each scan.
Data were reconstructed into 3D volumes with an isotropic voxel spacing of 50 μm and
scaled into Hounsfield units (HU). Using MicroView software (GE Healthcare
Biosciences) three signal-intensity thresholds (-200, -30, and 190 HU) were used to classify
each voxel as adipose, lean, or skeletal tissue, respectively. Custom software was used to
calculate tissue masses from assumed densities of 0.95 (adipose), 1.05 (lean), and 1.92
(skeletal) g/cm3, as previously reported 42.
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3.4.4

Histological analysis

Intact lumbar spine segments (L1-S1) and knees were isolated, fixed, decalcified and
paraffin embedded, as previously described43. Spines were sectioned sagittally, and knees
were sectioned coronally at a thickness of 5 μm using a microtome (Leica Microsystems:
Wetzlar, DEU). Lumbar spines were stained using a 0.1% Safranin-O/0.05% Fast Green.
Knees were stained with either 0.1% Safranin-O/0.05% Fast Green or 0.04% Toluidine
Blue. Sections were imaged on a Leica DM1000 microscope, with Leica Application Suite
(Leica Microsystems: Wetzlar, DEU).
To evaluate IVD degeneration, spine sections were scored by 2 independent scorers using
the modified Boos system44. Knee joint health was assessed using the murine Osteoarthritis
Research Society International (OARSI) histopathological scale45. Articular surfaces of the
medial femoral condyle (MFC), medial tibial plateau (MTP), lateral femoral condyle (LFC)
and lateral tibial plateau (LTP), were scored by two blinded observers and averaged. For
each knee joint surface, scores from 10 serial sections spanning 500 µM of the joint were
summed to represent OARSI score for each quadrant. Total scores from each of the four
quadrants were then added together to generate whole joint OARSI score. Thickness of
articular cartilage of the MTP and LTP was quantified using the OsteoMeasure7 Program
(v.4.2.0.1, OsteoMetrics Inc., Decatur, GA, USA). Articular cartilage thickness within each
quadrant was averaged using three serial sections spanning 150 μM of the weight-bearing
region of the knee. Using the same histomorphometry system, trabecular bone area was
calculated by measuring the total surface area of the bone between the articular cartilage
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and growth plate and subtracting the area of bone marrow. Measurements were taken for
both medial and lateral compartments of the joint and averaged from 3 serial sections.

3.4.5

Gene expression analysis

Thoracic IVDs (4-5 per mouse; 5-8 mice per diet/per timepoint) were isolated by
microdissection, placed in TRIzol reagent (Thermo Fisher Canada: Mississauga, ON,
CAN) and homogenized using a PRO250 tissue homogenizer (PRO Scientific: Oxford,
CT, USA). RNA was extracted according to manufacturer's instructions, quantified using
a NanoDrop 2000 spectrophotometer (Thermo Fisher Canada: Mississauga, ON, CAN),
and 0.5 µg was reverse transcribed into complementary DNA (cDNA) (iScript; Bio-Rad
Laboratories (Canada): Mississauga, ON, CAN). Gene expression was assessed by realtime PCR using a Bio-Rad CFX384 instrument. PCR analyses were run in triplicate using
120 ng of cDNA per reaction and 310 nM forward and reverse primers with 2x SsoFast
EvaGreen Supermix (Bio-Rad Laboratories (Canada): Mississauga, ON, CAN) using
optimized PCR parameters and primers (Table 3.4, Supplementary Table 2). Primers
were designed and validated to have efficiency values between 90 and 120%. Transcript
levels were calculated relative to a 6-point standard curve made from pooled cDNA
generated from murine IVD explants treated with lipopolysaccharide for 4 days (50
mg/mL; Thermo Fisher Canada: Mississauga, ON, CAN).

3.4.6

Immunohistochemistry

The intact spinal cord was removed, dissected to separate the upper (L1-L2) and lower (L3L6) segments of the lumbar enlargement, and fixed in 4% paraformaldehyde (PFA) for 24
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h at 4°. Tissues were cryoprotected for 4 days in 10% sucrose and embedded in optimal
cutting temperature compound (Tissue-Tek O.C.T; Sakura Finetek US: Torrance, CA,
USA) and stored at -20°C. Tissues were sectioned on a cryostat (Leica Microsystems:
Wetzlar, DEU) in the transverse plane at a thickness of 14 μm, thaw mounted onto gelatincoated slides, and stored at -80°C.
Slides were brought to room temperature, washed twice in PBS and blocked using 5%
donkey serum, 0.1% Triton X-100 in PBS for 2h at room temperature. Sections were
incubated overnight in a humidified chamber at 4ºC in 5% donkey serum in PBS (with
0.1% Triton-X) containing primary antibodies directed against glial fibrillary acidic protein
(GFAP) (1:500; G3893, Sigma-Aldrich: St. Louis, MO, USA), ionized calcium binding
adaptor molecule 1 (IBA-1) (1:1000; AB-10341, Abcam: Cambridge, UK), or calcitonin
gene-related peptide (CGRP) (1:750; BML-CA1137, Enzo Biochem: New York, NY,
USA). Slides were rinsed 3 x 10 min in PBS-T (PBS + 0.01% Triton X-100) and then
incubated for 45 min at room temperature with secondary antibodies diluted 1:500 in PBS:
Alexa Fluor 488 conjugated donkey anti-mouse IgG for GFAP (A-21202, Thermofisher:
Waltham, MA, USA); Alexa Fluor 594 conjugated donkey anti-rabbit IgG for Iba-1 (A21207, Thermofisher: Waltham, MA, USA); or Alexa Fluor 488 donkey anti-sheep IgG
for CGRP (A-11015, Thermofisher: Waltham, MA, USA). Slides were rinsed 3 x 10 min
in PBS, dipped in deionized water, and cover slips mounted using Fluoroshield Mounting
Medium with 4′,6-diamidino-2-phenylindole to visualize nuclei (ab104139, Abcam:
Cambridge, UK). Tissue sections were imaged using a Leica Microsystems DMI6000B
fluorescence microscope and DFC360FX camera with Leica Advanced Application Suite
software (Version 2.7.0-9329, Leica Microsystems: Wetzlar, DEU). A region of interest
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(ROI) was manually defined to contain lamellae 1-4 of the spinal cord dorsal horn using
ImageJ software. The dorsal horn was differentiated from surrounding white mater based
on brightfield images. Integrated density of fluorescence within the ROI was used to
quantify astrocyte/microglia density, and CGRP-immunoreactivity.

3.4.7

Serum analysis by Multiplex Assay

At euthanasia, blood was obtained by cardiac puncture, coagulated for 30 min at room
temperature, and centrifuged at 3 000 rpm for 10 min at 4°C to collect serum. Serum (n=56 mice per diet/per timepoint) was diluted 2-fold in DPBS and analyzed using the
Luminex™ 200 system (Luminex, Austin, TX, USA) by Eve Technologies Corp. (Calgary,
Alberta). Thirty-two markers were simultaneously measured in each serum sample using
the MILLIPLEX Mouse Cytokine/Chemokine 32-plex kit (Millipore, St. Charles, MO,
USA) according to the manufacturer's protocol. The multiplex assay quantified Eotaxin,
G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, KC, LIF, LIX, MCP-1, M-CSF, MIG,
MIP-1α, MIP-1β, MIP-2, RANTES, TNFα, and VEGF. The assay sensitivities range from
0.3 – 30.6 pg/mL for the 32-plex.

3.4.8

Statistical Analysis

For all assays except histopathological scoring of the joints, outcome measures for mice
within each time point were compared between the different diet groups by one-way
ANOVA with Tukey’s multiple comparisons test. For histopathological analysis, within
each timepoint scores for mice were compared between the different diet groups by non-
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parametric Kruskal-Wallis test with Dunn’s multiple comparison test. P < 0.05 was
considered significant. Statistical analysis was conducted using GraphPad Prism 8
(Graphpad Software: San Diego, CA, USA).
To assess the effect of diet, adiposity, knee OA and IVD degeneration on behavioral,
molecular, and histological changes assessed, bivariate and multivariate linear regression
models were used to identify which variables remained independently associated with the
other outcomes. Bivariate and multivariate modelling was conducted using STATA 16
(StataCorp LLC: College Station, TX, USA).

3.5
3.5.1

Results
Weights and adiposity

As expected, following 12, 24- and 40-weeks mice fed the high-fat and western diets
showed a significant increase in body mass and weight gain compared to age-matched
chow fed controls (Figure 3.1A). Analysis of body composition by micro-CT (Figure
3.1B) demonstrated that the increase in adiposity in mice fed the experimental diets was
accompanied by a significant decrease in the percentage of both lean and skeletal tissues
at all time points (Figure 3.1C). This analysis also showed a significant increase in overall
bone mineral density (BMD) in mice fed the high-fat diet at all timepoints, and at the 24and 40-week timepoints for mice fed the western diet, compared to age-matched chow fed
controls (Figure 3.1C).
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Figure 3.1: Chronic consumption of high-fat and western diets increases adiposity
and bone mineral density in C57BL/6N mice.
(A) At all timepoints, mice fed the high-fat and western diets showed significant increases
in overall weight and in weight-gain from baseline compared to age-matched chow fed
controls. (B) Representative reconstructed micro-CT images of mice following 40-weeks
of experimental diets. Isotropic surface-rendering of skeletal tissue (indicated in white) is
overlaid with a mid-coronal slice where lean tissue is indicated in red and adipose tissue is
indicated in yellow. (C) Quantitative micro-CT analysis of whole-body composition
showed a significant increase in adiposity and significant decreases in both percentage of
lean and skeletal and in mice fed the high-fat and western diet mice compared to agematched chow fed controls at all time points. A significant increase was also seen in bone
mineral density in mice following consumption of the high-fat and western diets at the 24and 40-week timepoints. n=9-16 mice per timepoint, per diet. Data are displayed as mean
± 95% CI; data points for each mouse are graphed within each group. *P<0.05, **P<0.01,
***P<0.001, ****P<0.0001 by 2-way ANOVA.
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3.5.2

Behavioral indicators of axial discomfort

We first investigated whether mice fed the high-fat or western diet showed behavioral
indicators of stretch-induced axial discomfort using three complimentary assays
established as indicators of discogenic back pain in a mouse model of degeneration40:
behavior during tail suspension, changes in spontaneous activity after tail suspension, and
tolerance to axial stretching in the grip force assay. In the tail suspension test, no significant
differences were observed between diet groups at any time point investigated (Figure
3.2A). Similarly, changes in spontaneously activity induced by the tail suspension assay
(locomotion pre versus post tail suspension) were not altered between experimental diet
groups and age-matched chow fed controls (Figure 3.2B). Grip force during axial stretch
was reduced in mice fed the high-fat diet compared to age-matched chow fed controls at
12- and 40-weeks and in mice fed the western diet at all time points compared to control
(Figure 3.2C), suggesting decrease tolerance to axial stretch.

3.5.3

Behavioral indicators of mechanical and cold sensitivity

Mechanical and cold sensitivity were assessed in the hind paw using the Von Frey assay
and by measuring the response of mice to the evaporative cooling of acetone, respectively.
Mice fed the western diet showed a significant increase in mechanical sensitivity at the 24and 40-week time points compared to age-matched chow fed controls, while mice fed a
high-fat diet showed a significant increase in sensitivity only at the 24-week timepoint
compared to controls (Figure 3.3A). In contrast, no significant difference was observed in
sensitivity to cold between mice in either experimental diet group compared to agematched chow fed controls at any time point (Figure 3.3B).
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Figure 3.2: Obesity induced by the high-fat and western diets reduces grip strength
but does not alter behavior in tail suspension.
(A) During tail suspension, the duration of time spent by mice immobile, in full extension,
rearing or self-supported was quantified. No significant differences were detected between
diet groups at any of the time points assessed. (B) Stretch-evoked discomfort was assessed
using the open field assay, in which the total distance covered in 5 min immediately before
(pre) and after (post) the 3 min tail suspension assay was quantified. Obesity induced by
the high-fat and western diets did not alter behavior of mice in open field compared to agematched chow fed controls at any of the time points assessed. However, a significant
difference was seen between mice fed a high-fat and western diet at the 40-week timepoint.
(C) Grip force during axial stretch was reduced in obese mice. Mice fed the high-fat diet
showed a significant decrease in grip force at the 12- and 40-week time points compared
to age-matched chow fed controls. Mice fed the western diet showed a significant decrease
in grip force compared to age-matched chow-fed controls at all time points. n=9-16 animals
per timepoint, per diet. Data are plotted mean ± 95% CI; data points for each mouse are
graphed within each group. *P<0.05, **P<0.01, ***P<0.001 by 2-way ANOVA.
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3.5.4

Spontaneous locomotion

Behavior and locomotion in open field was assessed for all mice over a 2 h period. Mice
fed the western diet showed a significant decrease in total distance travelled following 12
and 24 weeks compared to age-matched chow fed controls. Mice fed the high-fat diet
showed a significant reduction in locomotion following 24-weeks compared to agematched controls (Figure 3.3C). The number of rearing events was also significantly
decreased in mice fed the high-fat and western diets at the 40-week time point compared
to age-matched chow fed controls (Figure 3.3C).

3.5.5

Assessment of IVD degeneration

The effects of the high-fat and western diets on IVD health were assessed using both
histopathological evaluation and molecular analysis (Figure 3.4). On average, no overt
differences were detected in the histological appearance of lumbar IVDs between mice fed
either the high-fat or western diet for 12- and 24-weeks compared to age-matched chow
fed controls (Figure 3.4A). Accordingly, histopathological scoring using the modified
Boos system showed no significant differences in degeneration between the groups.
However, when data was analyzed by individual spinal level, mice fed the western diet
showed significantly lower scores than their high-fat or chow fed counterparts at the L6S1
spinal level at the 12-week timepoint (Figure 3.4B). Following 40 weeks on the
experimental diets, an accumulation of hypertrophic cells surrounded by a
glycosaminoglycan-rich pericellular matrix was consistently detected in the inner annulus
fibrosus of mice fed both the high-fat and western diets, but not in age-matched chow fed
control mice (Figure 3.4A – black arrows). Despite this observation, histopathological
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Figure 3.3: Obesity induced by a high-fat and western diet increases sensitivity to
mechanical stimulation and alters spontaneous locomotion.
(A) Mechanical Sensitivity of the hind paw was assessed by manual application of Von
Frey filaments using the Chaplin up-down method. Mice fed the western diet showed a
significant decrease in withdrawal threshold at the 24- and 40-week time points compared
to age-matched chow fed controls, indicative of increased mechanical sensitivity. Mice fed
a high-fat diet showed a significant decrease in withdrawal threshold at the 24-week
timepoint compared to control. (B) Sensitivity to cold was assessed by measuring the time
spent in behavior evoked by evaporative cooling of acetone (flicking, stamping or licking
of ventral surface of the paw) during the first 40s following application of acetone to the
ventral surface of the hind paw. No significant differences were seen between the diet
groups at any timepoint. (C) Spontaneous locomotor activity was recorded over three 2 hr
sessions and averaged. Mice fed the western diet showed a significant decrease in the total
distance travelled at the 12- and 24-week timepoint compared to age-matched chow fed
controls, while mice fed the high-fat diet showed a decrease at the 24-week timepoint. The
number of rearing events was significantly decreased in mice fed the high-fat and western
diets compared to controls at the 40-week timepoint. n=9-16 animals per timepoint, per
diet. Data are plotted mean ± 95% CI; data points for each mouse are graphed within each
group. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by 2-way ANOVA.
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scoring revealed no significant degeneration in the diet groups compared to chow fed
controls at the 40-week time point (Figure 3.4B). Histopathological analysis was paired
with qPCR to quantify expression of markers of inflammation, neural ingrowth, and matrix
degrading enzymes in thoracic IVDs to further investigate molecular changes associated
with diet-induced obesity. Mice fed the high-fat or western diets showed no significant
differences in the expression of the genes investigated at the 12-week timepoint compared
to age-matched chow fed controls (Figure 3.4C). Mice fed the high-fat diet showed no
significant differences in gene expression compared to chow fed controls at the 24-week
timepoint for any of the genes investigated. At the 40-week timepoint, mice fed the highfat diet showed increased expression of inflammatory mediators (Il-6, Ptsg2),
neurotrophins (Bdnf), as well as matrix degrading enzymes (Adamts5) compared to agematched chow fed controls (Figure 3.4C). Mice fed the western diet showed increased
expression of the inflammatory mediators Il-1b and Ptgs2 compared to chow fed controls
at 24 weeks; however, no significant differences in gene expression were detected at the
40-week timepoint (Figure 3.4C).

3.5.6

Assessment of degenerative changes in the knee

Since diet-induced obesity leads to other arthropathies, such as knee OA23, we investigated
degenerative changes to the knee joint as a potential contributor to the pain-related
behavioral outcomes we assessed. We focused this analysis on the 24- and 40-week
timepoints where changes in behavioral measures were most consistently identified. No
overt histological differences were detected in the knee joints of mice fed either the highfat or western diet for 24 weeks compared to age-matched chow fed controls (Figure
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Figure 3.4: Effect of diet-induced obesity on the intervertebral disc.
(A) Representative histological sections of the L6/S1 spinal level of the lumbar spine
stained with safranin-o/fast green from mice fed control chow, high-fat, or western diet for
12, 24, or 40 weeks. The accumulation of hypertrophic cells was detected within the inner
annulus fibrosus of mice fed the high-fat and western diets for 40 weeks (highlighted by
black arrows). (B) Evaluation of the grade of histopathological IVD degeneration using the
modified Boos scoring system showed no significant differences between mice fed the
control chow, high-fat or western diets at the 24- and 40-week timepoints. At the 12-week
timepoint, mice fed the western diet showed a significant decrease in the degenerative score
compared to mice fed chow and high-fat diets. n=9-16 animals per timepoint, per diet. Data
are analyzed by Kruskal-Wallis test. (C) SYBR-based qPCR of intact thoracic
intervertebral discs showed no significant difference between mice fed a chow, high-fat or
western diet at the 12-week timepoint for any genes investigated. At the 24-week timepoint,
significant increases in Il-1b and Ptgs2 expression were seen in mice fed the western diet
compared to control. By 40-weeks, significant increases in Il-6, Ptgs2, Bdnf and Adamts5
expression were seen in mice fed the high-fat diet compared to control. n=5-8 animals per
diet/per timepoint. Analyzed by one-way ANOVA. All data are plotted mean ± 95% CI;
data points for each mouse are graphed within each group. *P<0.05, ***P<0.001.

97

3.5A). Histopathological scoring using the OARSI system supported these observations
(Figure 3.5B). At the 40-week timepoint, mice fed the western diet showed decreased
proteoglycan staining in the medial femoral condyle (MFC) compared to age-matched
controls (Figure 3.5A), resulting in significantly higher OARSI scores (Figure 3.5B)
indicating early signs of osteoarthritis. However, no significant differences were seen in
the other compartments of the knee joint or in the cumulative OARSI scores for the whole
joint. In addition to histopathological analysis, cartilage thickness was measured by
histomorphometry. Although no significant differences in cartilage thickness were detected
in mice following 24 weeks on the experimental diets, mice fed the high-fat diet for 40
weeks showed a significant decrease in cartilage thickness specific to the lateral femoral
condyle compared to age-matched chow fed controls (Figure 3.5C). Histomorphometry
was similarly used to measure the relative surface area of trabecular bone between the
articular cartilage and growth plate. Mice fed the western diet for 40 weeks showed a
significant increase in subchondral trabecular bone compared to age-matched chow fed
controls specifically in the medial tibial plateau (Figure 3.5D), suggesting sclerosis of the
subchondral bone.

3.5.7

Analysis of sensory neuroplasticity within the lumbar spinal cord

To assess neuroplastic changes associated with neuroinflammation and chronic pain,
lumbar spinal cords from mice at the 40-week time point were assessed for markers of
astrocytes (glial fibrillary acidic protein, GFAP), microglia (ionized calcium-binding
adapter molecule 1, IBA-1), and nociceptive innervation (calcitonin gene-related peptide,
CGRP; Figure 3.6A). Although multiple mice in both the high-fat and western diet groups
showed increased GFAP and IBA-1 staining in the upper and lower lumbar spinal cord
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Figure 3.5: Effect of diet-induced obesity on the knee joint.
(A) Representative histological coronal sections of the medial knee compartment stained
with safranin-o/fast green from mice fed either control chow, high-fat, or western diet for
24- or 40- weeks. Images are oriented with the medial femoral condyle (MFC) located
superiorly, and the medial tibial plateau (MTP) inferiorly. White arrows indicate cartilage
damage, presenting as loss of proteoglycan staining and focal fibrillation of the cartilage,
and white boxes indicate osteophyte formation. (B) Histopathological grading of the knee
joints using the murine Osteoarthritis Research Society International (OARSI) scale
corresponding to MTP, MFC, lateral tibial plateau (LTP), and lateral femoral condyle
(LFC), combined to generate the summed score for the whole joint. Mice fed the western
diet for 40-weeks showed a significant increase in the degenerative score in the MFC
compared to those fed the control chow. However, no difference was seen in the whole
joint score between any of the groups at either timepoint. (C) Average articular cartilage
thickness. After 40 weeks on the high fat diet, mice presented with decreased articular
cartilage thickness on the LTP. No other differences were seen in any other joint
compartment. Data analyzed by Kruskal-Wallis test. (D) Percent trabecular bone in the
medial and lateral subchondral compartments of the tibia. Mice enrolled on the western
diet for 40 weeks exhibited significantly more trabecular bone in the medial compartment
for the tibia. n=9-16 animals per diet/per timepoint. Analyzed by one-way ANOVA. All
data are plotted mean ± 95% CI, *P<0.05.
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compared to the average values for chow fed controls, quantification of fluorescent
intensity within the dorsal horn showed no significant difference between diet conditions
for any of the proteins investigated (Figure 3.6B).

3.5.8

Circulating inflammatory factors

Luminex xMAP multiplex assays were used to quantify a panel of 32 cytokines,
chemokines, and growth factors in the serum of experimental mice. Mice fed a western diet
showed increased levels of interleukin (IL)-1β, IL-6, IL-10, and tumor necrosis factor alpha
(TNFα) at the 12- and 40-week timepoints in their serum, however, no significant
differences were seen when compared to chow fed control due to variability between
animals (Table 3.1). Despite this variability, at the 40-week timepoint a significant increase
in circulating monocyte chemoattractant protein 1 (MCP-1) was observed in mice fed a
western diet compared to chow-fed control (Table 3.1). Animals fed a western diet showed
for 24-weeks also showed significantly lower levels of circulating eotaxin and IL-1α
compared to chow fed controls, but no other differences in any of the other cytokines
investigated (Table 3.5, Supplementary Table 3).

3.5.9

Linear regression analysis

To directly examine associations in the context of the observed variability within each
experimental group in our study, linear regression modeling was conducted to determine
whether diet, adiposity or age were predictors of behavioral, histological, or systemic
outcomes (Table 3.2). Bivariate modelling demonstrated that both adiposity and age are
independent predictors of multiple indicators of pain including stretch-induced axial
discomfort (grip force), mechanical sensitivity (Von Frey assay) and spontaneous
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Figure 3.6: Effect if diet-induced obesity on neuroplastic changes within the lumbar
spinal cord.
(A) Representative images showing transverse sections of the dorsal horn of the lumbar
spinal cord used for immunohistochemical analysis of neuroplastic changes associated with
chronic pain. Tissues were isolated from mice following 40 weeks of experimental diet.
Slides were stained for glial fibrillary acidic protein (GFAP), ionized calcium-binding
adapter molecule 1 (IBA1) and calcitonin gene-related peptide (CGRP). Yellow boxes
indicate the region of interest for high magnification images (second row) for GFAP and
IBA-1 (B) The fluorescence intensity averaged across the region of interest (lamellae 1-4
of the dorsal horn) of the upper (L1-L2) and lower (L3-L6) lumbar spinal cords. Mice fed
a high-fat or western diet for 40-weeks showed no significant differences in
immunoreactivity for any of the proteins investigated. n = 6-8 animals/group. Individual
data points of the same colour indicates the same animal. Data are plotted mean ± 95% CI.
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Table 3.1: Multiplex analysis of cytokines, chemokines and growth factors in serum.
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whether diet, adiposity or age were predictors of behavioral, histological, or systemic
outcomes (Table 3.2). Bivariate modelling demonstrated that both adiposity and age are
independent predictors of multiple indicators of pain including stretch-induced axial
discomfort (grip force), mechanical sensitivity (Von Frey assay) and spontaneous
locomotion (open field). Despite their association with behavioral alterations, neither
adiposity nor age were associated with measures of joint degeneration or levels of most
circulating factors assessed (Table 3.2). Exceptions to this were TNFα and MCP-1, which
were associated with age (bivariate), and the western diet (multivariate), respectively
(Table 3.2). When diet, adiposity and age were accounted for, age was found to be the
most robust predictor of all outcomes measured (Table 3.2). Aside from age, the
multivariate model also showed that diet and adiposity are covariates for grip force and
rearing in open field, respectively (Table 3.2). To determine if histopathological scores for
joint damage were independently associated with behavioral indicators of pain, bivariate
and multivariate regression modeling was completed. In this study, no significant
association was detected between histopathological scores for IVD degeneration and painrelated behaviors. A weak but significant association was detected between
histopathological scores for knee OA and grip force, but not for any of the other behavioral
metrics assessed (Table 3.6, Supplementary Table 4).

3.6

Discussion

Obesity is one of the largest modifiable risk factors for the development of both IVD
degeneration and associated LBP35,36, yet the biological mechanisms underlying this
association are currently unknown. With the prevalence of obesity on the rise1, it is
necessary to address this problem and identify underlying pathogenic mechanisms. The
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Table 3.2: Impact of diet-induced obesity and age on behavioral, molecular, and
histological changes.
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current study was designed to investigate the longitudinal effects of diet-induced obesity
on inflammation, IVD degeneration and pain using the mouse as a preclinical model. We
show that obesity induced by both a high-fat and high-fat/high-sugar western diet led to
behavioral indicators of pain in as little as 12-weeks, preceding gross structural changes to
the IVD and knee joints. Following 40 weeks, changes in cellular morphology within the
inner AF of the IVD were detected in mice fed both obesogenic diets compared to chowfed controls; however, these changes were not associated with increased histopathological
degeneration. Chronic consumption of the high-fat diet was associated with increased
expression of Il-6, Ptgs2, Bdnf, Adamts-5, and Mmp-3 within the IVD and a decrease in
articular cartilage thickness within the lateral tibial plateau. In contrast, chronic
consumption of the western diet was associated with increased expression of Il-1b and
Ptgs2 within the IVD, histopathological features of early OA, subchondral bone sclerosis,
and increased serum MCP-1 levels. These findings highlight the complex interplay
between diet, adiposity, pain, inflammation, and joint health.
Rodent models have proven useful to study IVD and joint biology since they allow insight
into biological processes that regulate tissue homeostasis and degeneration. Numerous
models have been described in which IVD degeneration is induced through genetic
manipulation, surgical disruption, chemical injection or aberrant mechanical loading46.
Although these studies contribute to understanding the cellular and molecular basis of IVD
degeneration, few investigate the association with pain47. Given the discordance between
structural IVD degeneration and pain development in humans10,48,49, and pre-clinical
models50, it is important to investigate both pain and structural IVD degeneration and their
relation to one another. Although pain cannot be directly measured in animals, several
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indirect, quantitative behavioral assays have been developed to evaluate pain-like
behaviors for a variety of different pain states51,52. Many of these behavioral metrics are
not specific to back pain and are used to assess joint, inflammatory, and neuropathic
pain53,54. Stretch-induced axial discomfort has however been established as a reliable
measure of axial low back pain40. In the current study, mice fed obesogenic diets showed
significant impairments in grip force at all timepoints compared to control mice, suggesting
axial discomfort. In contrast, no significant difference was detected in the tail suspension
assay between mice fed obesogenic diets and controls. This potentially contradictory data
may be influenced by the nature of the tail suspension assay, which was originally used to
test depressive behavior in mice55. In addition to musculoskeletal pathologies, obesity is
also associated with depression33. In fact, recent studies demonstrated that mice fed a highfat diet for 8 weeks showed increased time immobile in tail suspension, interpreted as a
characteristic of depression-like behavior56. This behavior is in contrast to both genetic
and age-related mouse models of IVD degeneration and axial pain which show increased
time rearing in tail suspension57,58. This confounding factor may impact the outcome of tail
suspension in the diet-induced obesity model, and consequently the interpretation of our
findings.
In addition to indicators of stretch-induced axial discomfort, obese mice also displayed
mechanical but not thermal (cold) hypersensitivity of the hind-paw. These alterations are
consistent with results seen in a model of surgically induced IVD degeneration, where
intradiscal injection of PBS induced mechanical hypersensitivity in rats59. However, these
results directly contrasted a genetic model of IVD degeneration, where SPARC-null mice
show thermal but not mechanical hypersensitivity compared to WT control39. While the
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mechanisms underlying these differences are unclear, mechanical sensitivity is common in
both inflammatory and neuropathic pain models60, and different models of pain are likely
to impact nociception through different pathogenic mechanisms61. Obesity also appeared
to impact non-reflexive (spontaneous) pain behaviors including distanced travelled and
rearing in open field. These measurements have been previously shown to be decreased in
both inflammatory and neuropathic pain models62. Taken together, our findings indicate
that mice fed a high-fat or western diet display pain-related behaviors starting at the 12week timepoint and persisting until the 40-week timepoint.
Previous studies established that high-fat diet-induced obesity accelerates OA progression
in mice23,26; however, pain-related behaviors were found to be independent of osteoarthritis
severity23. As IVD degeneration has been associated with many of the pain-related
behaviors reported for OA38, we characterized both IVD degeneration and OA-associated
knee degeneration in our experimental mice to account for both as factors contributing to
pain. Histopathological scoring of lumbar IVDs did not reveal significant degeneration
caused by the high-fat or western diet at any timepoint. However, mice fed both obesogenic
diets showed a consistent accumulation of hypertrophic-like cells in the inner annulus
fibrosus at 40 weeks, suggesting early degenerative change. Moreover, increased
expression of inflammatory mediators (Il-1b, Il-6, Ptgs2), matrix degrading enzymes
(Adamts5) and neurotrophins (Bdnf) were detected in mice fed the high-fat and western
diets. These inflammatory cytokines are known drivers of IVD pathogenesis associated
with ECM degeneration and expression of neurogenic factors such as NGF and BDNF that
can contribute to pain63. Similarly, significant histopathological degeneration in the knee
was only detected at the 40-week timepoint in mice fed the western diet. Linear regression
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modeling indicates that the behavioral indicators of pain assessed are independent of joint
degeneration, except for the grip force assay for which knee OA was a significant predictor
of impairment. Together these findings indicate that diet-induced obesity may potentially
accelerate the progression of structural IVD degeneration and knee OA at the later
timepoints; however, these changes are mild and are likely independent of most painrelated behaviors.
Findings from the current study suggesting that pain-related behaviors precede molecular
and structural alterations in joint tissues raise questions related to the source of the pain
observed. These findings are however consistent with the hypothesis that pain is
multifactorial. Obesity is considered a state of chronic inflammation associated with
increases in several circulating inflammatory cytokines such as TNFα and IL-6 in
humans64. Inflammation has been shown to contribute to peripheral and central
sensitization and may lead to hyperexcitability of the nervous system and chronic pain 65.
Consistent with these findings, we demonstrate that consumption of the western diet led to
increased levels of circulating MCP-1 in mice, a pro-algesic mediator that can increase
primary afferent neuron activity66,67. Obesity may also impact central pain processing; in
mice consumption of a high-fat diet increases the activation of microglia68 while exposure
of cultured astrocytes to saturated fatty acids induces cytokine release and astrocyte
inflammation69. These neuroplastic changes can contribute to central sensitization through
multiple mechanisms, including increased release of inflammatory factors contributing to
modulation of synaptic activity65 . Although the averaged values of GFAP and IBA-1
expression in the spinal cord were not significantly different between diet groups in our
study, multiple mice in both the high-fat and western diet groups showed increased
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activation of both microglia and astrocytes at the 40-week timepoint. These alterations to
the nociceptive pathways at either the peripheral or central level may contribute to the pain
response seen. While not assessed, obesogenic diets also lead to painful diabetic
neuropathy, or nerve damage, which may also contribute to the pain phenotype observed70.
Given the diverse impacts of obesity, it could be postulated that obesity-related pain may
arise either from hyperexcitability or damage to nociceptive pathways in conjunction with
tissue damage, and these contributions may differ between animals and over time. A
limitation of this study is the utility of behavioral tests used to assess pain in our model.
While they serve as indicators of pain in other models, many assays used in the current
study also have been used to test muscle strength71 and psychiatric disorders55 which may
be impacted by obesity33,72. To further explore whether these behavioral responses are due
to pain, future studies may wish to pharmacologically inhibit nociceptive pathways to
confirm that behavioral differences are due to pain.
Although the average weight gain was similar between the two obesogenic diets evaluated
in this study, important differences in outcomes were detected. Mice fed the western diet
showed a more consistent pain response compared to control at all timepoints than mice
fed the high-fat diet. Furthermore, at the 40-week timepoint knee osteoarthritis and
increases in systemic inflammation were only seen in mice fed the western diet. These
findings highlight the importance of dietary composition in the study of obesity. In the
context of OA, dietary fatty acid and carbohydrate composition can significantly impact
joint health24,73. Diets high in saturated fatty acids or

-6 polyunsaturated fatty acids

(PUFAs) induce more severe metabolic dysregulation and OA progression than diets
enriched with

-3 PUFAs24. Aside from fat, diets high in sucrose can also accelerate OA
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progression independent of weight gain73. These findings may explain our results, as the
composition of the western diet is higher in both saturated fats and sucrose than the highfat diet. Dietary composition has also been shown to impact IVD health. Diets rich in
advanced glycation end-products (AGE) precursors accelerate IVD degeneration in mice
in parallel with insulin resistance74.
A confounding factor in the interpretation of our findings was the substantial variability
for many of the outcomes investigated, including substantial differences in weight gain
between mice on both obesogenic diets. Despite controlling for genetics using an inbred
strain, susceptibility to diet-induced obesity can be affected by social stress, microbiome
composition and epigenetic mechanisms75–77. Accounting for this variability, previous
studies in mice demonstrated that cartilage damage induced by a high-fat diet is
proportional to adiposity23. In the current study, adiposity did not predict histopathological
measures of joint degeneration; however, adiposity and age were significant predictors of
behavioral indicators of pain. Highlighting the complexity of these models, increased
adiposity was also not directly associated with increased circulating cytokine levels in our
study. In humans, obese individuals can be classified as metabolically healthy
(metabolically healthy obese (MHO)). MHO individuals are at less risk for developing
obesity-related complications than metabolically abnormal obese individuals, including
OA78. The mechanisms underlying MHO are not well understood, however, genetic,
epigenetic and environmental factors are thought to play a role79,80. As adiposity does not
directly correlate with systemic or neuroinflammation in the current model, it is important
to investigate all aspects of metabolic syndrome (i.e. circulating lipids, glucose,
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cytokines/adipokines, blood pressure) on both the musculoskeletal and nervous system in
future models to determine their contribution to disease progression.
Taken together, this study highlights the complexity of the relationship between obesity,
IVD degeneration and pain. Mice fed a high-fat or western diet showed pain-related
behaviors that preceded structural joint degeneration in both the IVD and knee. The
chronology of these findings may be of clinical importance, as pain may affect the
progression of radiographic joint degeneration. While not directly investigated in IVD
degeneration, knee pain has shown to be a predictor of accelerated radiographic OA
through inflammation and reduced mobility81, which is also seen in IVD degeneration82.
This raises the intriguing possibility that back pain may be both a consequence of structural
IVD degeneration in the current model, and a contributor to it.
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3.7

Supplementary Figures

Figure 3.7, Supplementary Figure 1: Spontaneous locomotion (Continued).
Spontaneous Locomotion activity was recorded over three 2 hr sessions and averaged. (A)
Mice fed the western diet showed a significant decrease in the average movement velocity
at all timepoints compared to age-matched chow fed controls, while mice fed the high-fat
diet showed a decrease at the 24-week timepoint. (B) The amount of time spent in the
anxiety-inducing center area of the open field enclosure was decreased in mice fed the
high-fat and western diets compared to controls but not significant at any timepoint. n=916 animals per timepoint, per diet. Data are plotted mean ± 95% CI; data points for each
mouse are graphed within each group. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by
one-way ANOVA.
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Figure 3.8, Supplementary Figure 2: SYBR-based qPCR of thoracic IVDs
(continued).
SYBR-based qPCR of intact thoracic intervertebral discs showed no significant difference
between mice fed a chow, high-fat or western diet at the 12-week and 24-week timepoint
for any genes investigated. At 40-weeks a significant increase was seen in Mmp12
expression in mice fed a high-fat diet compared to chow control. n=5-8 animals per diet/per
timepoint. Analyzed by one-way ANOVA. All data are plotted mean ± 95% CI; data points
for each mouse are graphed within each group. *P<0.05, ***P<0.001.
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Table 3.3, Supplementary Table 1: Experimental diet compositions.
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Table 3.4, Supplementary Table 2: Real-time qPCR primer sequences.
NCBI Gene
Primer Sequence 5’ → 3’
Name
Il6 Fwd
TCTCTGCAAGAGACTTCCATCCAGT
Il6 Rev
AGTAGGGAAGGCCGTGGTTGTCA
Il1b Fwd
CCCTGCAGCTGGAGAGTGTGGA
Il1b Rev
TGTGCTCTGCTTGTGAGGTGCTG
Ptgs2 Fwd
GGCGCAGTTTATGTTGTCTGT
Ptgs2 Rev
CAAGACAGATCATAAGCGAGGA
Bdnf Fwd
TCATACTTCGGTTGCATGAAGG
Bdnf Rev
GACCTCTCGAACCTGCCC
Adamts5 Fwd
GGAGCGAGGCCATTTACAAC
Adamt5 Rev
GCGTAGACAAGGTAGCCCACTTT
Mmp3 Fwd
TTGTCCCGTTTCCATCTCTCTC
Mmp3 Rev
TTGGTGATGTCTCAGGTTCCAG
Adamts4 Fwd
GAGGAGGAGATCGTGTTTCCAG
Adamts4 Rev
CAAACCCTCTACCTGCACCC
Mmp12 Fwd
GCTTACCCCAAGCTGATTTCC
Mmp12 Rev
ATGTTTTGGTGACACGACGGA
Mmp13 Fwd
CTTCTTCTTGTTGAGCTGGAACTC
Mmp13 Rev
CTCTGTGGACCTCACTGTAGACT
Ngf Fwd
TGATCGGCGTACAGGCAGA
Ngf Rev
GCTGAAGTTTAGTCCAGTGGG
Vegf Fwd
CACTGGACCCTGGCTTTACT
Vegf Rev
GCAGTAGCTTCGCTGGTAGA
Annealing Temperature: 60°C
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Table 3.5, Supplementary Table 3: Multiplex analysis of cytokines, chemokines and
growth factors in serum (continued).
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Table 3.6, Supplementary Table 4: Association between behavioral indicators of
pain and histological joint damage.
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4.2

Chapter Summary

Introduction: Despite being a major cause of disability worldwide, clinical treatment of
intervertebral disc (IVD) degeneration and associated back pain is limited to symptomatic
relief. While epidemiological studies have highlighted obesity as a major risk factor for the
development of IVD degeneration and back pain, the biological mechanisms underlying
this association are unknown. A potential mediator of obesity-associated IVD degeneration
is the nuclear receptor peroxisome proliferator-activated receptor delta (PPARδ), as its
ligands are dysregulated in obesity and its deletion has previously been shown to play a
protective role in articular cartilage in the context of osteoarthritis.
Methods: Ex vivo, intact mouse IVD explants were treated with a synthetic agonist of
PPARδ (GW501516) and gene expression and glycosaminoglycan breakdown in the IVD
were evaluated. In vivo, the role of PPARδ was assessed in an age- and obesity-induced
models of IVD degeneration using male and female Col2-Cre;Ppardfl/fl conditional
knockout mice (Ppard KO). Following 50 weeks of experimental diet, mice were assessed
for histological and molecular indicators of joint degeneration and behavioral indicators of
pain.
Results: PPARδ is expressed in the NP and AF and responds to PPARδ agonism by
increased expression of downstream target genes, indicating PPARδ is functionally active
in the IVD. Following 50 weeks of western diet, male mice showed indicators of IVD
degeneration - changes not detected in female mice - and osteoarthritis induction in both
sexes. Ppard KO mice showed protection from age-associated IVD degeneration but not
from obesity-associated IVD degeneration or knee osteoarthritis. Pain-related behaviors
were detected more consistently in female than male mice, despite a lack of
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histopathological IVD degeneration. Bivariate and multivariate regression modeling
indicates that sex and diet are robust predictors of many behavioral, histopathological, and
molecular changes observed, while loss of PPARδ is only a predictor of knee OA when
sex and diet are accounted for. Regression analysis also reveals that alterations in painrelated behavior are independent of structural IVD degeneration.
Conclusion: While PPARδ deletion may protect from age-associated IVD degeneration, it
does not protect against obesity-associated IVD degeneration but may influence the pain
associated with joint damage. This data demonstrates the complex, and context-dependent
role of PPARδ in the IVD and the need to evaluate multiple models of IVD degeneration
for potential of clinical translation of novel therapeutic targets.

4.3

Introduction

Low back pain (LBP) is the single largest cause of disability worldwide, with a lifetime
prevalence over 84% in Canada1,2. Despite efforts to improve the clinical management of
LBP, treatments are limited to symptomatic relief without treating the underlying cause of
the pain3. While several tissues appear to be involved in LBP, including the paraspinal
muscles, ligaments, and facet joints4–6, degeneration of the fibrocartilaginous intervertebral
disc (IVD) is believed to be the major contributor to pain in approximately 40% of cases4.
IVD degeneration has traditionally been considered a condition of “wear and tear”;
however, this paradigm has shifted in recent years with the realization that IVD
degeneration is an active process starting at the cellular level, ultimately leading to
structural and functional failure7,8. Although the etiology of IVD degeneration remains
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unclear, it appears to be multifactorial, as epidemiological studies have highlighted several
modifiable and non-modifiable risk factors7–10. Of these, obesity is a major modifiable risk
factor for the development of IVD degeneration and LBP. Obesity — defined as a body
mass index (BMI) over 30 — substantially increases the risk of developing several
metabolic, cardiovascular, neurological and musculoskeletal diseases11. In the spine,
increased body weight is associated with indices of lumbar disc degeneration including
disc space narrowing and decreased lumbar disc signal intensity detected by MRI12,13.
Increased fat mass is also associated with increased LBP intensity and associated
disability14. With the prevalence of obesity nearly tripling over the last 30 years11, it poses
a large public health concern.
Despite the clinical associations between obesity, IVD degeneration, and LBP, the
biological mechanisms underlying this association remain elusive. While increased
mechanical load is thought to underlie in part these associations15, systemic factors
including the chronic low-grade inflammation associated with obesity are also likely
involved16. Metabolic and inflammatory abnormalities associated with obesity contribute
to the development of osteoarthritis (OA) 17, a degenerative musculoskeletal disease with
many similarities to IVD degeneration18. Obesity is associated with chronic metabolic
disorders including hypertension, diabetes mellitus and dyslipidemia, collectively known
as metabolic syndrome19. In the context of OA, it is postulated that each component of
metabolic syndrome may independently contribute to disease progression, as
comprehensively reviewed by Zhuo et al.20. Specifically, alterations in the release of
systemic factors (inflammatory cytokines, adipokines), nutrient exchange, advanced
glycation end-products (AGEs) levels and glucose/lipid metabolism are believed to be
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major contributors to OA progression17,20.

Studies from multiple groups have

demonstrated that obesity induced by a high-fat diet accelerates the progression of both
age- and surgically-induced knee OA using mouse and rat models21–25, accompanied by
behavioral indicators of pain21.
While not fully explored in the context of musculoskeletal diseases, the peroxisomeproliferator activated receptor (PPAR) family are current therapeutic targets for the
management of metabolic syndrome26. The PPAR family of nuclear receptors consists of
three isoforms (alpha, delta, gamma), that are activated by circulating fatty acid ligands26,
and play distinct roles in energy balance and lipid/ glucose metabolism27. The two most
studied isoforms, PPARα and PPARγ, are highly expressed in the liver and adipose,
respectively, and agonists of these receptors are being used clinically for obesity-associated
conditions including dyslipidemia and type II diabetes mellitus26,28,29. Studies investigating
the role of PPARγ in cartilaginous tissues demonstrated that cartilage-specific deletion of
PPARγ leads to spontaneous OA development in mice30. In contrast to PPARα and PPARγ,
PPARδ has broad expression patterns and affects glucose and lipid metabolism, cell
differentiation, proliferation, apoptosis and immune regulation31. Using transgenic mouse
models, studies have shown PPARδ agonism improves insulin resistance, fat burning, and
muscle endurance32–34; however, PPARδ agonism has also been shown to induce catabolic
processes within articular cartilage and chondrocytes35,36, suggesting tissue-specific or
context dependent functions of PPARδ. In explant and cell culture models, PPARδ
agonism leads to aggrecan and glycosaminoglycan degradation in cartilage through
increased expression of Mmp-3 and Adamts-535,36, matrix remodelling enzymes implicated
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in both OA and IVD degeneration37,38. Moreover, mice with deletion of PPAR in articular
cartilage are protected from cartilage damage in a post-traumatic model of OA35.
Given that its ligands are dysregulated in obesity and the potential role it plays in articular
cartilage, the present study aimed to investigate the role of PPARδ in the IVD. We first
investigated the effects of PPARδ activation using an ex vivo organ culture system and
validated that PPARδ was functionally active within the IVD. We then examine the role of
PPARδ in the IVD in vivo using Col2-Cre;Ppardfl/fl mice to delete PPARδ within the NP
and inner AF. We used this mouse model to examine the role of PPARδ in both ageassociated and obesity-associated IVD degeneration and pain, using both male and female
mice to specifically investigate sex as a variable.

4.4
4.4.1

Methods
Mice and Ex Vivo organ culture

Ten-week-old, C57BL/6N mice (Charles River: Wilmington, MA, USA) were used to
isolate lumbar and thoracic spinal segments. Following removal of surrounding ligaments
and musculature, IVDs were isolated from the vertebral columns using a stereoscope. Intact
IVDs were used in ex vivo culture experiments. NP and AF tissue were further
microdissected (as reported previously39) for gene expression analysis. For ex vivo organ
culture, isolated IVDs (NP, AF, CEP) were equilibrated in organ culture media (DMEM
low glucose (1g/L), 1% FBS, 1 % penicillin/streptomycin) overnight at 2% O2. On the
following day, explants were treated with PPARδ agonist GW501516 (Cedar Lane Labs:
Burlington, ON, CAN) at concentrations of 0.01, 0.1, or 1 μM in organ culture media for
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4 or 7 days (6-7 IVDs per treatment) at 2% O2. Media was changed every 48 hours and
DMSO-treated explants served as vehicle controls.
PPARδ-KO mice were generated by breeding mice carrying the Ppard gene flanked by
loxP sites (Ppardfl/fl; B6.129S4-Ppardtm1Rev/J, The Jackson Laboratories)40 to mice carrying
Cre recombinase under control of the type II collagen promotor (Col2-Cre)41, and
genotyping was performed as previously reported41. Mice without cre-recombinase were
used as controls (Ppard fl/fl;Col2-Cre- hereinafter referred to as WT) and cre-positive mice
used as knockouts (Ppard fl/fl; Col2-Cre+ hereinafter referred to as Ppard KO).
To determine the role of PPARδ in the IVD, male and female mice were aged to 14 (n=913 per sex) or 25-months (n=4 male) of age and spinal tissues were harvested for
histological and molecular analysis. To determine the role of PPARδ in obesity-induced
joint degeneration, (Supplementary Figure 4.1) mice were fed standard chow (Envigo
2018) until 10-weeks of age, when they were randomized into one of two diet groups (n =
9-13 mice per diet/ per genotype/ per sex;): standard chow (18% kcal fat, 58% kcal
carbohydrate) or a high-fat, high-sugar western diet (45% kcal fat, 41% kcal carbohydrate;
Envigo TD.10885) (Supplementary Table 3.1). Mice remained on the experimental diets
until sacrifice at 60 weeks-of-age (50 weeks on diet). Mice were housed in standard cages
and maintained on a 12 hr light/dark cycle, with food and water were consumed ad libitum;
food consumption and body weight were measured weekly. All aspects of the study were
conducted in accordance with the policies and guidelines set forth by the Canadian Council
on Animal Care and were approved by the Animal Use Subcommittee of the University of
Western Ontario (protocol 2017-154; Appendix B).
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4.4.2

Dimethylmethylene blue assay

The dimethylmethylene blue dye binding assay was performed on digested tissue explants
and media collected from IVD explant cultures. Following 4 days in culture, explants were
digested for 3 days in papain digest (125 μg/mL; Millepore Sigma Canada: Oakville, ON,
CAN) at 60°C. The dimethylmethylene blue dye binding assay was performed as
previously described42, and absorbance values were measured at a wavelength of 595 nm,
with a reference wavelength of 655 nm on the Tecan Safire plate reader. GAG
concentration in the media and tissue content were calculated based on a chondroitin sulfate
standard curve, and GAG release into the media was normalized to the total GAG in each
sample following papain digest.

4.4.3

Histological analysis

For ex vivo organ cultures, one lumbar IVD from each treatment group was fixed overnight
in 4% PFA, decalcified for 24h in TBD-2 (Thermo Fisher Canada: Mississauga, ON, CAN)
and paraffin embedded. For the in vivo experiments, intact lumbar spine segments (L1-S1)
and knees were isolated, fixed, decalcified and paraffin embedded, as previously
described43. IVD explants and lumbar spines were sectioned sagittally, and knees were
sectioned coronally at a thickness of 5 μm using a microtome (Leica Microsystems:
Wetzlar, DEU) and stained using 0.1% Safranin-O/0.05% Fast Green or 0.04% Toluidine
Blue, using methods previously described43,44.
To evaluate IVD degeneration, spine sections were scored by 2 independent scorers using
the modified Boos system45. Knee joint health was assessed using the murine Osteoarthritis
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Research Society International (OARSI) histopathological scale46. Articular surfaces of the
medial femoral condyle (MFC), medial tibial plateau (MTP), lateral femoral condyle (LFC)
and lateral tibial plateau (LTP), were scored by two blinded observers and averaged. For
each joint surface, scores from 10 serial sections spanning 500 µM of the joint were
summed to represent OARSI score for each quadrant. Total scores from each of the four
quadrants were then added together to generate whole joint OARSI score.

4.4.4
Intact

Gene expression analysis
IVDs

were

placed

were

placed

in

TRIzol

reagent

(Thermo Fisher

Canada: Mississauga, ON, CAN) (n=5-6 thoracic/lumbar IVDs per ex vivo treatment
group; 4-5 thoracic IVDs per mouse from 5-8 mice per diet/per timepoint) and
homogenized using a PRO250 tissue homogenizer (PRO Scientific: Oxford, CT, USA). To
assess tissue-specific differences in gene expression, NP and AF tissue were further
microdissected (as reported previously39) from WT mice and placed in in TRIzol reagent
(Thermo Fisher Canada: Mississauga, ON, CAN) and homogenized manually using a
pestle or using a PRO250 tissue homogenizer (PRO Scientific: Oxford, CT, USA) for NP
and AF samples, respectively. RNA was extracted according to manufacturer's instructions
and

quantified

using

a NanoDrop 2000

spectrophotometer

(Thermo Fisher

Canada: Mississauga, ON, CAN). For the ex vivo and in vivo studies 0.5 µg RNA was
reverse

transcribed

into

complementary

DNA

(cDNA)

(iScript;

Bio-

Rad Laboratories (Canada): Mississauga, ON, CAN), while 0.15 μg RNA was reverse
transcribed for the NP/AF comparison due to sample size limitations. Gene expression was
assessed by real-time PCR using a Bio-Rad CFX384 instrument. PCR analyses were run
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in triplicate using 120 ng of cDNA per reaction and 310 nM forward and reverse primers
with 2x SsoFast EvaGreen Supermix (Bio-Rad Laboratories (Canada): Mississauga, ON,
CAN) using optimized PCR parameters and primers at an annealing temperature of 60°C
(Supplementary Table 4.1). Primers were designed and validated to have efficiency
values between 90 and 120%. For the ex vivo study and NP/AF comparison, transcript
levels were calculated using ΔΔCt, with data normalized for input based on Ribosomal
protein S29 (Rps29) and expressed relative to DMSO treated controls or AF samples,
respectively. For the in vivo studies, transcript levels were calculated relative to a 6-point
standard curve made from pooled cDNA generated from murine IVD explants treated with
lipopolysaccharide for 4 days (50 mg/mL; Thermo Fisher Canada: Mississauga, ON,
CAN).

4.4.5

Micro-computed tomography (Micro-CT)

At sacrifice, mice in the diet study were immediately imaged by micro-CT (Locus Ultra,
GE Healthcare Biosciences). Whole-body scans were acquired using 1000 projection
images obtained over a single 16 s rotation (80 kv, 55 mA tube current, 16 ms exposure).
A calibrating phantom composed of air, water and cortical bone-mimicking epoxy (SB3;
Gammex, Middleton WI, USA) was scanned together with each of the animals. Data were
reconstructed into 3D volumes with an isotropic voxel spacing of 154 μm and scaled into
Hounsfield units (HU). Using MicroView software (GE Healthcare Biosciences) three
signal-intensity thresholds (-200, -30, and 190 HU) were used to classify each voxel as
adipose, lean, or skeletal tissue, respectively. Custom software was used to calculate tissue
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masses from assumed densities of 0.95 (adipose), 1.05 (lean), and 1.92 (skeletal) g/cm3.
Volumetric measures were averaged over voxel volume47.

4.4.6

Behavioral measures of pain

In the week prior to endpoint, mice in the diet study were assessed for behavioral indicators
of pain. All mice were moved from conventional housing to the neurobehavioral testing
facility two weeks prior to testing and habituated to all behavioral tests one week prior to
data collection. On data collection days, animals were habituated to the testing room for 1
h before test start. To avoid confounding variables associated with the diurnal cycle, all
behavioral testing was completed between 8 and 11 AM.

4.4.6.1

Stretch-induced axial discomfort

Stretch-induced axial discomfort was measured using the grip force assay, as described
previously48–50. For the grip force assay mice grabbed onto a metal bar attached to a grip
force meter, and gently pulled back by their tails to exert axial stretch. Tolerance was
assessed by measuring the grip strength (Grip Force Meter, Stoelting Co., Wood Dale, IL),
in grams, for each mouse at the point of release.

4.4.6.2

Hind limb sensitivity to cold and mechanical stimuli

Hind paw sensitivity to cold was assessed by measuring the time spent in behavior evoked
by evaporative cooling of acetone (flicking, stamping or licking of ventral surface of the
paw) during the first 40 s following application of 50 μL acetone to the ventral surface of
the hind paw. Mechanical sensitivity of the hindlimb was measured through application of

138

calibrated Von Frey filaments (Stoetling Co., Wood Dale, IL) to the plantar surface of the
hind paw for 3 s or withdrawal. 50% withdrawal threshold was calculated using the
Chaplan up-down method51, with a starting stimulus intensity of 1.4 g.

4.4.6.3

Spontaneous activity

Spontaneous locomotor activity was assessed using open field activity monitors (AccuScan
Instruments, Omnitech Electronic, Columbus, OH). Mice were placed into individual
boxes and their activity was monitored over 30 min.

4.4.6.4

Rotarod

Locomotor capacity was assessed with rotarod (30 mm diameter; Omnitech Electronics
Inc: Columbus, OH, USA) that accelerated (0-30 rpm) for the first 60s and maintained at a
maximal speed for an additional 240s. The experimental endpoint occurred when the
animal fell from the rotating rod, detected by an infrared sensor. Animals that fell off once
within the first 30 s were placed back onto the rod, and video recordings were used to
confirm latency times.

4.4.7

Pharmacological manipulation of pain

To assess whether behaviors indicative of stretch-induced axial discomfort (grip force) and
mechanical sensitivity (Von Frey) were caused by pain, assays were repeated on all mice
following administration of a weak opioid (Tramadol hydrochloride, 50 mg/kg, intraperitoneal (i.p.); Medisca: Richmond, BC, CAN). Testing was conducted 20 min and 45
min after tramadol injection for the Von Frey and grip force assay, respectively.
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4.4.7.1

Tail flick test

To assess the anti-nociceptive effects of tramadol, the latency of tail flick response was
measured prior to injection, 20 min and 60 min after injection. Tail flick latency is the
amount of time between applying heat to the tip of the tail through submersion in a hot
water bath (set to 52°C), and voluntary tail withdrawal. The cutoff time was 12 s to prevent
tissue injury and the antinociceptive response to tramadol was expressed as a percentage
of the maximal possible effect (%MPE), as previously reported52.

4.4.7.2

Spontaneous locomotion

To assess whether tramadol had a sedative effect, spontaneous activity in open field was
measured over 10 min, 35 min after tramadol injection.

4.4.8

Statistical analysis

For all assays except histopathological scoring of the joints, groups of male and female
mice were compared between the different diet groups and genotypes by two-way ANOVA
with Tukey’s multiple comparisons test. For histopathological scores, within each
timepoint mice were compared between the different diet groups by non-parametric MannWhitney U test. P < 0.05 was considered significant. Statistical analysis was conducted
using GraphPad Prism 8 (Graphpad Software: San Diego, CA, USA).
To assess the effect of sex, genotype, and diet on behavioral, molecular, and histological
changes, bivariate and multivariate linear regression models were used to identify which
variables remained independently associated with all other outcomes. Bivariate and
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multivariate modelling was conducted using STATA 16 (StataCorp LLC: College Station,
TX, USA).

4.5
4.5.1

Results
IVD cells express PPARδ and respond to pharmacological
activation

To determine whether PPARδ was expressed and functional, intact IVD explants from 10week-old WT mice were treated with increasing concentrations of the synthetic PPARδ
agonist GW501516 for 4 or 7 days (Figure 4.1A). After both 4 (Figure 4.1B) and 7 days
(Figure 4.1C) of treatment, expression of known downstream PPARδ effector genes
including Pyruvate Dehydrogenase Kinase 4 (Pdk4) and Angiopoietin-Like 4 (Angptl4)
were significantly increased with agonist treatment. To assess the relative expression of
PPARδ in distinct IVD compartments, expression of Ppard was assessed NP and AF
tissues isolated by microdissection from 10-week-old WT mice. NP cells showed
significantly lower expression of Ppard than AF cells (Figure 4.1D). Genes involved in
metabolism and oxidative stress altered by PPARδ agonism in chondrocytes were also
evaluated36. No significant difference in the expression levels of ATP-binding cassette
transporter (Abca1), carnitine palmitoyltransferase 1A (Cpt1a), Glutathione S-transferase
A4 (Gsta4), or Insulin Induced Gene 1 (Insig1) were detected in the IVD following agonist
treatment (Figure 4.11, Supplementary Figure 2). After 7 days, treatment with 0.01 μM
GW501516 significantly upregulated the expression of Thioredoxin-interacting protein
(Txnip) in IVD explants (Figure 4.11, Supplementary Figure 2B).
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Figure 4.1: PPARδ is expressed in the IVD and responds to pharmacological agonism.
(A) Representative histological sections of IVD explants cultured for 4 or 7 days in media
supplemented with DMSO (vehicle control) or the PPARδ-specific agonist GW501516
(0.01 μM, 0.1 μM, or 1 μM) stained with Safranin-O/Fast Green. (B & C) SYBR-based
real-time qPCR analysis of IVD explants treated with GW501516 for 4 or 7 days show
significant increases in the expression of known PPARδ targets Pdk4 and Angptl4 (n=5-6
biological replicates). (D) SYBR-based real-time qPCR analysis of Ppard expression in
NP and AF tissues isolated by microdissection. The expression of Ppard in the AF is
significantly higher than expression in the NP (n=10-11). Data are presented as mean ±
95% CI. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by One-way ANOVA with
Tukey’s test compared to DMSO control for organ culture and by Welch’s t-test for
comparison of AF and NP tissue samples.
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4.5.2

Effect of PPARδ activation on proteoglycan levels in the IVD

To determine the effects of PPARδ activation on glycosaminoglycan (GAG) levels within
intact IVDs, explants were treated with a vehicle control (DMSO), 0.01 μM, 0.1 μM, or 1
μM GW501516 for 4 days (Figure 4.12, Supplemental Figure 3). While no gross
morphological changes were observed, an apparent loss of proteoglycan staining was
observed in explants cultured in the presence of 1 μM GW501516 compared to DMSO
control (Figure 4.12, Supplementary Figure 3A). To confirm these observations, levels
of GAG were quantified in both the tissue explants and culture media using the
dimethylmethylene blue dye binding (DMMB) assay. PPARδ agonism was associated with
a slight but not statistically significant increase in the release of GAG into the media
(Figure 4.12, Supplementary Figure 3B). SYBR-based qPCR analysis was used to assess
the expression of extracellular matrix genes and genes involved in matrix degradation. No
significant differences were seen in the expression of matrix degrading enzymes (Figure
4.12, Supplementary Figure 3C) or extracellular matrix components (Figure 4.12,
Supplementary Figure 3D).

4.5.3

Deletion of PPARδ may protect against age associated IVD
degeneration

We next assessed the effect of PPARδ deletion on age associated IVD degeneration. A
conditional knockout mouse was generated using the Col2-Cre that our lab has
demonstrated is expressed throughout the nucleus pulposus, inner two thirds of the AF and
cartilage endplate, in addition to in addition to cartilaginous tissues, similar to other Col2-
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Cre transgenic mouse lines53,54. WT and Ppard KO mice were aged to either 14 or 25
months-of-age and IVD health was assessed through histological analysis. At the 14-month
timepoint, no discernable differences were detected in IVD health between WT and Ppard
KO mice (Figure 4.2A). Accordingly, histopathological scoring showed no difference
between WT and Ppard KO mice at any individual spinal level or in the average
histopathological score in both male and female mice (Figure 4.2B). At the 25-month
timepoint, male WT mice demonstrated advanced IVD degeneration, including a loss of
proteoglycan content in the NP, accumulation of fibrotic matrix in the NP, and the loss of
a distinct boundary between the NP and AF. In contrast, Ppard KO mice show more
consistent maintenance of overall IVD structure and preservation of the NP cellularity and
proteoglycan content (Figure 4.2C). While histopathological scoring indicated that Ppard
KO animals had less degeneration on average than WT mice, the differences were not
significant (Figure 4.2D).

4.5.4

Wild-type and Ppard KO mice gain weight on the western diet

To investigate whether PPARδ would play a similar role in obesity-induced IVD
degeneration, at 10 weeks of age male and female WT and Ppard KO mice were
randomized into groups fed either a high-fat/high-sugar western diet or chow control for
50 weeks (Figure 4.10, Supplemental Figure 1). As expected, following 50 weeks on the
experimental diet both male and female mice fed the western diet showed a significant
increase in body mass (Figure 4.3A) and weight gain (Figure 4.3B) compared to sex and
genotype-matched chow fed controls. Analysis of whole-body composition by micro-CT
demonstrated that for both WT and Ppard KO, male and female mice fed the western diet
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Figure 4.2: Loss of Ppard alters age associated IVD degeneration.
Representative images of mid-sagittal sections of lumbar IVDs stained with SafraninO/Fast Green from 14-month old or 25-month-old wild-type (WT) and PPARδ knockout
(Ppard KO) mice paired with evaluation of the grade of histopathological degeneration
using the modified Boos scoring system. (A) At 14 months-of-age, no differences in was
detected in the histological appearance of IVD tissues between WT and PPARδ KO mice.
(B) At the 14-month timepoint, no differences in histopathological scores of IVD
degeneration were seen between genotypes at either individual lumbar spinal levels or in
the average degeneration score calculated for all lumbar IVDs. (C) At 25 months-of-age,
male Ppard KO mice lacked histopathological signs of advanced IVD degeneration seen
in WT mice, including a loss of proteoglycan content and accumulation of fibrotic matrix
in the NP and the loss of a distinct boundary between the NP and AF. (D) At the 25-month
timepoint, male Ppard KO mice showed lower degenerative scores at individual lumbar
levels compared to WT; however, these changes did not result in significant differences in
histopathological scores. Data are plotted mean ± SEM and analyzed by Mann-Whitney Utest (n=9-13 for 14-month timepoint; n=3-5 for 25-month timepoint). *P<0.05,
***P<0.001.
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Figure 4.3: Weight and adiposity.
(A) Following 50 weeks on the western diet, WT and Ppard KO mice showed a significant
increase in body weight compared to chow-fed control. (B) Mice fed the western diet
showed increased weight gain from baseline compared to chow-fed controls, regardless of
sex or genotype. (C) Representative reconstructed micro-CT images of mice following 50weeks of experimental diets. Isotropic surface-rendering of skeletal tissue (indicated in
white) is overlaid with a mid-coronal slice where lean tissue is indicated in red and adipose
tissue is indicated in yellow. Micro-CT based analysis of whole-body composition
demonstrated a significant increase in (D) adipose tissue mass in all groups of mice fed the
western diet compared to chow-fed controls; however, no differences were detected in (E)
bone mineral density (BMD). n=9-13 animals per genotype, sex, and diet. Data are plotted
as mean ± 95% CI. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by 2-way ANOVA
with Tukey’s test.
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showed an increase in adipose tissue compared to chow controls (Figure 4.3D). No
significant difference was seen in bone mineral density between diet groups in either WT
or Ppard KO mice (Figure 4.3E).

4.5.5

Deletion of PPARδ does not protect against obesity related IVD
degeneration

The effects of the western diet on IVD health was assessed through histopathological
evaluation (Figure 4.4) and molecular analysis (Figure 4.5). In males, mice fed the western
diet showed indicators of IVD degeneration not evident in chow control in both genotypes
(Figure 4.4A). Histopathological changes included abnormal matrix deposition within the
NP and a loss of clear demarcation between the NP and AF. Although no overt differences
were detected between WT and Ppard KO mice, the western diet induced more consistent
degeneration in male Ppard KO mice than in WT mice. Accordingly, histopathological
scoring using the modified Boos scoring system showed significant increases in
degeneration in the L6S1 spinal level of male Ppard KO mice fed a western diet compared
to their chow-fed controls, but not in WT mice (Figure 4.4B). In females, no overt
differences were detected in the histological appearance of the lumbar IVDs between the
diet groups or genotypes (Figure 4.4C). As such, histopathological scoring did not show
any differences in degeneration of lumbar IVDs between diet groups in female WT or
Ppard KO mice (Figure 4.4D).
To further investigate the role of PPARδ and changes associated with diet-induced obesity,
SYBR-based qPCR was used to quantify the expression of extracellular matrix components
(Figure 4.5A), matrix degrading enzymes (Figure 4.5B), and markers of inflammation and
neural in-growth (Figure 4.5C) in thoracic IVDs. Despite no changes in IVD
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Figure 4.4: Effect of diet-induced obesity and PPARδ deletion on IVD health.
Representative mid-sagittal sections of lumbar IVDs stained with Safranin-O/Fast Green
from male (A) and female (C) wild-type (WT) and PPARδ knockout (Ppard KO) mice fed
either a chow control or western diet for 50 weeks. Male mice fed a western diet showed a
loss of the demarcation between the NP and AF compared to chow control. This was
observed in both WT and Ppard KO male mice, to a greater extent in Ppard KO animals.
In female mice, no observable differences were seen between diet group or genotype.
Evaluation of the grade of histopathological IVD degeneration using the modified Boos
scoring system showed that (C) male Ppard KO mice fed a western diet showed
significantly greater degeneration than their chow-fed controls at the L6/S1 spinal level.
(D) No significant differences in histopathological scoring were seen between diets in
female mice. n=9-13 mice per sex, genotype, and diet. Data is presented as mean ± 95%
CI. *P<0.05 by Mann-Whitney U test.
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histopathology, at 14 months-of-age male Ppard KO mice demonstrated increased
expression of Acan, Mmp3, Mmp13, and Il-1b compared to WT mice (chow diet controls).
Following 50 weeks of western diet, male WT mice showed a significant increase in the
expression of Acan and Il-1b compared to chow fed controls, while male Ppard KO mice
showed a significant increase in Il-1b expression compared to chow fed controls (Figure
4.5A & 4.5C). Male Ppard KO mice in the western diet group also showed a significant
increase in Il-1b expression compared to male WT mice in the western diet group (Figure
4.5C). Similar patterns of gene expression were not detected in female mice. No
differences in IVD gene expression were detected between female WT and Ppard KO
mice. In female mice, changes associated with western-diet induced obesity were limited
to down-regulation of Col1a1 expression in WT mice compared to chow fed controls
(Figure 4.5A).

4.5.6

Deletion of PPARδ does not protect against obesity-related knee
OA

Diet-induced obesity contributes to other arthropathies, such as knee OA29. Moreover, loss
of Ppard protects from surgically induced posttraumatic OA35. We therefore examined the
role of PPARδ in obesity-induced OA. In male mice, chronic consumption of the western
diet in both WT and Ppard KO mice led to increased erosion of the articular cartilage and
osteophyte formation at the joint margins compared to sex-matched chow fed controls
(Figure 4.6A). This corresponded to a significant increase in histopathological scores
(Figure 4.6B). A similar trend was observed in female mice (Figure 4.6C). While female
WT mice had more degeneration on average when fed the western diet compared to chow
fed controls, this difference was not significant. Consumption of the western diet induced
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Figure 4.5: Effect of diet-induced obesity and PPARδ KO on IVD gene expression.
SYBR-based qPCR analysis was conducted to assess the expression of (A) extracellular
matrix genes, (B) matrix remodeling genes, and (C) proinflammatory and neurotrophic
factors in IVDs of wild-type (WT) and PPARδ knockout (Ppard KO) mice fed either a
chow control or western diet for 50 weeks. Male Ppard KO mice showed increased
expression of Acan, Mmp3, Mmp13, and Il-1b compared with WT mice. No significant
differences were detected in female Ppard KO mice compared to WT controls. WT male
mice fed the western diet showed significantly increased expression of Acan and Il-1b,
while male Ppard KO mice fed a western diet only showed significant increases in Il-1b
compared to genotype-matched chow-fed controls. Female WT mice fed the western diet
showed significant decreases in Col1a1 expression compared to chow-fed controls. n=8
animals per sex, genotype, and diet. Data are plotted mean ± 95% CI. *P<0.05, **P<0.01,
***P<0.001 by 2-way ANOVA with Tukey’s test.
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Figure 4.6: Effect of diet-induced obesity and PPARδ deletion on knee joint health.
(A & C) Representative coronal sections of the medial knee compartment stained with
toluidine blue male and female wild-type (WT) and PPARδ knockout (Ppard KO) mice
fed either a chow control or western diet for 50 weeks. Images are oriented with the medial
femoral condyle (MFC) located superiorly, and the medial tibial plateau (MTP) inferiorly.
Western diet-induced obesity was associated with indicators of osteoarthritis in all groups
of mice assessed compared to chow-fed controls, marked by erosion of articular cartilage
(arrows) and osteophyte formation (outlined in white dashed box). (B & D) Quantification
of joint degeneration using the murine OARSI histopathological scoring system showed
significant increases in joint degeneration in mice fed the western diet compared to chow
fed controls for male WT and Ppard KO mice as well as female Ppard KO mice. n=4-8
animals per sex, genotype, and diet. Data are plotted mean ± 95% CI. *P<0.05, **P<0.01
by 2-way ANOVA with Tukey’s test.
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a significant increase in histopathological scores in female Ppard KO mice compared to
chow fed controls (Figure 4.6D).

4.5.7

Behavioral indicators of stretch-induced axial discomfort

To investigate the association between obesity, back pain, and the potential role of PPARδ,
we first investigated whether mice fed the western diet showed behavioral indicators of
stretch-induced axial discomfort. Decreased grip force during axial stretch has been
previously established as an indicator of discogenic back pain in a mouse model of IVD
degeneration38. Loss of PPARδ did not alter grip force in either male or female mice
(Figure 4.7A). In male WT and Ppard KO, mice fed the western diet showed slight
decreases in grip force during axial stretch, but these differences were not statistically
different from chow fed control. In female WT and Ppard KO, mice fed the western diet
showed a significant reduction grip force during axial stretch, indicative of axial discomfort
(Figure 4.7A). To determine whether these behaviors were due to pain, the grip force assay
was repeated on all mice following administration of a dose of the weak opioid tramadol
(50 mg/kg I.P.). For all mice, the anti-nociceptive properties of the drug at this dosage were
confirmed with the tail-flick assay (Figure 4.13, Supplementary Figure 4) and potential
sedative effects of the drug were evaluated by measuring voluntary open field locomotion
(Figure 4.14, Supplementary Figure 5). In male mice, tramadol treatment did not
significantly alter grip force in any group (Figure 4.7B). In WT and Ppard KO female
mice, tramadol treatment did not significantly affect grip force, however, the baseline
significant difference associated with western diet-induced obesity in Ppard KO mice was
no longer evident (Figure 4.7C).
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Figure 4.7: Diet-induced obesity reduces grip strength in female mice.
(A) Stretch-induced axial discomfort was assessed in all groups of chow (control) and
western diet fed mice. Loss of PPARδ did not alter grip force in either male or female mice.
Female wild-type (WT) and PPARδ knockout (Ppard KO) mice fed the western diet
showed reduced resistive grip force during axial stretch compared to chow-fed controls.
To determine whether this was associated with pain, the grip force assay was repeated on
all mice after receiving a dose of the weak opioid tramadol (50 mg/kg I.P.). (B) In male
mice, tramadol did not significantly affect grip force in any group. (C) In female WT mice,
tramadol did not significantly alter grip force in mice on both diets and did not prevent the
significant difference associated with western diet-induced obesity. In female Ppard KO
mice, tramadol did not significantly improve grip force in either diet group; however, the
significant difference associated with western diet-induced obesity was no longer evident.
Graphs on the left show the percent of baseline, which represents the grip force following
tramadol treatment normalized to the pre-treatment (baseline) values for each animal.
Graphs on the right show the average grip fore (g) for mice in each group in the absence
and following administration of tramadol. n=9-13 mice per sex, genotype, and diet. Data
are plotted mean ± 95% CI. **P<0.01 between diets in each treatment group; indicates
significant (P<0.05) tramadol-induced differences in grip force for mice fed the chow
(black) or western (red) diet by 2-way ANOVA with Tukey’s test.
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4.5.8

Behavioral indicators of cold and mechanical sensitivity

Cold sensitivity was assessed by measuring the response to evaporative cooling of acetone
on the hind-paw. Cold sensitivity was not affected by loss of PPARδ or by western dietinduced obesity in either male or female mice (Figure 4.8A). Mechanical sensitivity was
then measured in the hind paw using the Von Frey assay. Loss of PPARδ did not alter
mechanical sensitivity in either male or female mice (Figure 4.8A). In males and female,
WT mice fed the western diet showed a significant decrease in tolerance to mechanical
stimulation compared to sex-matched chow fed controls. In both male and female Ppard
KO mice, no difference in mechanical sensitivity was seen in mice fed the western diet
compared to chow fed controls (Figure 4.8B). To assess whether these behavioral
differences to mechanical stimulation were due to pain, the Von Frey assay was repeated
on all mice following administration of a dose of the weak opioid tramadol (50 mg/kg I.P.).
In male (Figure 4.8C) and female (Figure 4.8D) mice, tramadol significantly decreased
mechanical sensitivity (increased withdrawal threshold) and prevented the baseline
differences detected in mechanical sensitivity caused by western diet-induced obesity.

4.5.9

Behavioral indicators of physical function and spontaneous
locomotion

Locomotor capacity was first assessed using an accelerating rotarod assay where the
outcome measure was time to fall. Loss of PPARδ did not alter locomotor capacity in the
rotarod assay in either male or female mice (Figure 4.9A). Moreover, western diet-induced
obesity did not affect performance of male mice in the rotarod assay; no significant
difference was seen in time to fall in either WT or Ppard KO mice compared to chow fed
controls (Figure 4.9A). In females however, western diet-induced obesity was associated
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Figure 4.8: Diet-induced obesity increases sensitivity to mechanical stimuli in wildtype mice.
(A) Sensitivity to cold was assessed by measuring the time spent in behavior evoked by
evaporative cooling of acetone following application to the ventral surface of the hind paw.
No differences were detected between any of the groups. (B) Mechanical sensitivity of the
hind paw was assessed by manual application of Von Frey Filaments using the Chaplin updown method. Male and female wild-type (WT) mice fed the western diet showed
increased mechanical sensitivity compared to chow-fed controls, indicated by a decreased
tactile response threshold. Mechanical hypersensitivity was not detected following
consumption of the western diet in PPARδ knockout (Ppard KO) mice. To determine
whether mechanical sensitivity was associated with pain, the assay was repeated on all
mice after receiving a dose of the weak opioid tramadol (50 mg/kg I.P.). In (C) male and
(D) female mice, administration of tramadol significantly decreased mechanical
sensitivity; withdrawal thresholds in mice fed the western diet were not different from those
of chow-fed controls. Graphs on the left show the percent of baseline, which represents the
withdrawal thresholds following tramadol treatment normalized to the pre-treatment
(baseline) values for each animal. Graphs on the right show the average grip fore (g) for
mice in each group in the absence and following administration of tramadol. n=9-13
animals per sex, genotype, and diet. Data are plotted mean ± 95% CI. *P<0.05 between
diets in each treatment group; indicates significant (P<0.05) tramadol-induced
differences in withdrawal threshold for mice fed the chow (black) or western (red) diet by
2-way ANOVA with Tukey’s test.
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Figure 4.9: Diet-induced obesity affects physical function and locomotion.
(A) Locomotor capacity was assessed using an accelerating rotarod assay. No significant
differences were seen in male mice between diet groups or genotypes. In female mice,
obesity induced by the western diet was associated with decreased motor function in both
wild-type (WT) and PPARδ knockout (Ppard KO) mice compared to chow-fed controls.
(B-D) Spontaneous activity was measured over 30 min in open field. No differences in
spontaneous activity were observed between WT and Ppard KO mice. Compared to chowfed controls, WT male mice fed the western diet showed reduction in distance and velocity
of locomotion as well as vertical activity (rearing); changes not observed in Ppard KO
mice. Compared to chow-fed controls, female WT and Ppard KO mice fed the western diet
showed reduction in distance and velocity of locomotion as well as vertical activity
(rearing). n=9-13 animals per sex, genotype, and diet. Data are plotted mean ± 95% CI.
*P<0.05, **P<0.01, ***P<0.001 by 2-way ANOVA with Tukey’s test.
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with a significantly decreased time to fall compared to chow fed controls, for both WT
and Ppard KO mice (Figure 4.9A).
Spontaneous locomotion in open field was also assessed for all mice over a 30 min period.
Loss of PPARδ did not alter total locomotion, velocity of movement or rearing in either
male or female mice (Figure 4.9B-D). Male WT mice fed the western diet showed a
significant decrease in total distance travelled (Figure 4.9B), average velocity (Figure
4.9C), and the number of rearing events (Figure 4.9D) compared to sex-matched chow fed
controls. However, these differences were not observed in male Ppard KO mice. In
females, both WT and Ppard KO mice fed the western diet showed significant decreases
in the total distance travelled, average velocity, and the number of rearing events compared
to sex-matched chow fed controls (Figure 4.9B-D). These data suggest that diet-induced
obesity impairs physical function in female, and to a lesser degree, in male mice.

4.5.10

Statistical modeling

To account for the large amount of variability within the data and outcome measures
assessed in the diet study, linear regression modeling was conducted to assess whether sex,
genotype or diet were predictors of the behavioral, histological, and molecular differences
observed (Table 4.1). Bivariate modeling demonstrated that the western diet alone was a
significant predictor of all behavioral alterations except for cold sensitivity, as well as
histopathological degeneration of the knee and alterations in extracellular matrix gene
expression in the IVD (Table 4.1). Sex was found to be an independent predictor of rotarod
performance, spontaneous locomotion, histopathological changes to the IVD, and
expression of inflammatory and matrix degrading enzymes (Mmp3, Mmp13, Adamts4, Il1b, Bdnf). When sex, genotype and diet were adjusted for using multivariate analysis,
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Table 4.1: Impact of sex, genotype, and diet on behavioral, molecular and histological
changes.
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similar trends were seen for all the outcomes measured, with sex and diet being covariates
for many behavioral and histological outcomes. Focusing on histological outcomes, sex,
diet, and genotype were all significant predictors of histopathological knee OA, while sex
and diet were significant predictors of IVD degeneration (Table 4.1). In addition to looking
at the association between sex, diet, and genotype on behavioral outcomes, we wanted to
determine whether histopathological joint damage was predictive of pain-related behavior,
independent of sex, diet, and genotype. To do so we constructed another bivariate and
multivariate linear regression model (Table 4.3, Supplementary Table 2), and this
analysis indicated that knee OA was associated with alterations to grip force and
differences in spontaneous locomotion; however, IVD degeneration was not significantly
associated with any of these behavioral outcomes.

4.6

Discussion

Previous research suggests that the nuclear receptor PPARδ plays a catabolic role in
articular cartilage, and that genetic deletion protects against both post-traumatic and ageassociated OA35,55. Our study represents the first examination of the role of PPARδ in the
IVD and the role of PPARδ in an obesity-induced model of IVD degeneration and
osteoarthritis. The present study shows that PPARδ is expressed and functionally active in
the IVD. We evaluated the effect of PPARδ inactivation on age- and obesity-associated
IVD degeneration in vivo using Col2-Cre;Ppardfl/fl mice to delete PPARδ within the NP
and inner AF. With age, Ppard KO mice showed considerably less IVD degeneration than
WT controls, yet in a western diet-induced obesity model, Ppard KO mice showed a higher
proportion of moderate-severe IVD degeneration compared to WT animals. Moreover, loss
of PPARδ in joint tissues appeared to modulate behavioral indicators of pain and physical
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function. Taken together, these finding illustrate a complex, and likely context-dependent
role of PPARδ in the IVD and articular cartilage.
A member of the nuclear receptor superfamily, PPARδ acts as a transcription factor whose
ligands are fatty acids and their metabolites, ultimately altering transcription of
downstream target genes33,56. Previous studies have highlighted common downstream
targets of PPARδ in chondrocytes as well as other tissues including Pdk4 and Angptl436,57,
which we showed were induced in IVD explants treated with the PPARδ agonist
GW501516. These findings indicate that PPARδ is functionally active in the IVD. In
articular cartilage explants, PPARδ agonism induces proteoglycan degradation, mediated
through upregulation of matrix degrading enzymes including Mmp3 and Adamts535.
Although, IVD explants treated with the PPARδ agonist showed a loss of safranin-o
staining within the NP, no significant differences were seen in the expression of any matrix
degrading enzymes investigated. These findings may be impacted by the use of intact IVDs
in organ culture and potential differential effects of PPARδ agonism in its distinct tissue
types. Anatomically, the IVD is a heterogeneous structure composed of three distinct, yet
interdependent tissues: the gelatinous nucleus pulposus (NP), the fibrocartilaginous
annulus fibrosus (AF), and cartilage endplates. In adults, the major cell type of the NP are
chondrocyte-like NP cells, which secrete a matrix very similar to that of articular cartilage,
in contrast to AF cells which are phenotypically more similar to fibroblasts58. Gene
expression analysis in the current study demonstrated that Ppard expression is significantly
higher in the AF than in the NP, highlighting the need to evaluate the effect of PPARδ
activation in each tissue type independently.
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Previous work by our group demonstrated that deletion of PPARδ in articular cartilage
protects against both surgically-induced35, and age-associated knee OA55. Consistent with
these findings, deletion of PPARδ within the IVD appears to protect from age associated
IVD degeneration, largely within the NP. In our current study, analysis of whole IVD gene
expression at 14 months-of-age (a timepoint not associated with histopathological change)
showed increased expression of aggrecan as well as genes involved in matrix degradation
(Mmp3, Mmp13) and inflammation (Il-1b) in male Ppard KO mice. While these results
suggest early degenerative changes, inhibitors of IL-1β signaling and matrix
metalloproteinases significantly impact the effects of these proteins59,60, and their
expression levels were not quantified and may counteract this increased expression. Further
studies are however required to examine the underlying mechanisms behind this protective
effect, specifically focused on characterizing molecular changes within IVD subcompartments in Ppard KO mice over time.
Given the protective effect of PPARδ deletion in age-associated IVD degeneration, we
wanted to determine whether this phenotype would be recapitulated in a model of dietinduced obesity. Since PPARδ ligands are dysregulated in obesity33 we postulated that its
deletion would protect against both obesity-induced IVD degeneration and osteoarthritis.
In contrast to our hypothesis, our findings demonstrated that western diet-induced obesity
accelerated IVD degeneration in male Ppard KO mice. Moreover, a greater proportion of
male Ppard KO mice fed the western diet showed severe degeneration than did male WT
mice fed the western diet, although these differences were not significant. Like in the IVD,
western diet-induced obesity accelerated OA progression in both WT and Ppard KO mice.
Although histopathological scores of OA severity were not different between Ppard KO
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and WT mice on the western diet, statistical modeling identified genotype as a significant
predictor of knee joint damage when sex and diet were accounted for. Taken together, these
findings underscore a context dependent role for PPARδ in joint degeneration.
While the exact role of PPARδ is not known in the IVD, PPARδ activation regulates the
transcription of many genes involved with lipid metabolism in chondrocytes, including
enzymes associated with fatty acid oxidation35,36. These studies postulated that in a posttraumatic model of OA, PPARδ-mediated cartilage degeneration may result from increased
production of reactive oxygen species (ROS) as a consequence of increased fatty acid
oxidation35. While this increase in ROS production may be detrimental to cartilage or the
IVD under physiological conditions, PPARδ-mediated lipid catabolism may be essential
in pathological conditions such as obesity. Studies investigating the role of diet-induced
obesity determined that free fatty acids induce lipotoxicity in chondrocytes leading to cell
death61. As a major regulator of lipid metabolism, PPARδ may directly contribute to the
prevention of lipotoxicity. Supporting this, studies in human skeletal muscle cells
demonstrated that PPARδ activation prevents lipoxicity, through reductions in fatty-acid
induced inflammation and endoplasmic reticulum stress62. In addition to the direct effects
of PPARδ deletion, alterations in PPARα and PPARγ signaling should also be considered,
as share common ligands with PPARδ and therefore may contribute to obesity-induced
changes in joint tissues63. Together, these putative mechanisms may contribute to the
context-specific role demonstrated for PPARδ in joint degeneration.
Although there are many similarities in the initiation and progression of IVD degeneration
and OA (as reviewed in18), our data highlights important differences. Consistent with our
previous study in wild-type mice64, animals fed a western diet often showed moderate to
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severe knee OA compared to chow control, while alterations to the IVD were subtle and
histopathological degeneration was localized to a single spinal level (L6-S1). In the knee,
metabolic alterations associated with obesity are postulated to be the major contributor to
joint degeneration. Supporting this, leptin deficient mice become obese yet do not develop
knee OA, suggesting that systemic factors may play a key role in obesity-induced OA65. In
the IVD, the relative contributions of mechanical and metabolic factors to obesity-induced
degeneration remain unknown. While speculative, the data from the current study suggests
that biomechanical factors may play a more substantial role in obesity-associated IVD
degeneration. In this study, obesity-induced histopathological IVD degeneration was
localized to the lowest lumbar spinal level (L6-S1). In humans, accelerated IVD
degeneration at the lumbosacral joint (L5S1) is attributed to increased mechanical loading
at this site66. If systemic factors were the major contributor to obesity-associated IVD
degeneration in our model, we would expect to see a more homogenous pattern of IVD
degeneration at multiple spinal levels; observations not seen in the current study. However,
the analysis of IVD degeneration was limited to a single timepoint in the current study and
it may be that generalized IVD degeneration may follow a more chronic exposure to the
obesogenic diet. It should also be noted that in addition to altered mechanical loading, the
size and geometry of IVDs differ based on spinal levels67, which may impact the diffusion
of nutrients and systemic molecules into the IVD thereby impacting levels of systemic
metabolic effectors. Future studies should explore the relative contributions of mechanical
and metabolic factors in the development of obesity-induced IVD degeneration and back
pain.
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Despite the utility of using rodent models to study IVD biology, few studies also assess the
clinical problem associated with IVD degeneration - pain68. In humans and animals, there
is often a discord between radiographic IVD degeneration and pain69,70. For example, two
animals may have equally degenerative IVDs, yet have different pain-related behaviors70.
Although pain cannot be directly measured in animals, several indirect, quantitative
behavioral assays have been developed to evaluate pain-like behaviors for distinct pain
states71,72. While many behavioral metrics are non-specific and are used to assess OA
pain73, stretch-induced axial discomfort is a validated measure of axial low back pain50. In
the current model, western diet induced obesity was associated with stretch-induced axial
discomfort in female mice fed the western diet, measured using the modified grip force
assay. To determine whether these differences were truly a measure of pain, mice were
treated with Tramadol, a centrally acting opioid analgesic previously shown to improve
grip strength and mechanical hypersensitivity in other pain models74–76. However, in the
current study, obesity-associated differences in grip force were not altered by tramadol.
Since grip force is also used to assess muscle strength77, and neuromuscular deficits have
been suggested as an initiating factor in obesity-induced OA21, we postulate that obesityinduced neuromuscular deficits may contribute to the behavioral differences observed and
should be further explored in the context of IVD degeneration and back pain.
Obesity induced by the western diet in WT mice was also associated with mechanical, but
not thermal hypersensitivity of the hind paw; findings that were consistent with previous
work from our group64. Mechanical sensitivity was inhibited by tramadol, indicating that
these behavioral differences were likely as a result of pain. Interestingly, Ppard KO mice
did not show obesity-induced mechanical sensitivity, despite having increased prevalence
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of IVD degeneration and knee OA. While the mechanisms underlying this phenotype in
Ppard KO mice are not understood, previous work done by our group has demonstrated
that subcutaneous injection of a PPARδ antagonist reduced pain-related behaviors in a
surgically-induced model of OA, despite not improving structural joint degeneration78.
Together, these findings demonstrate that western diet-induced obesity induces pain related
behavior in mice, and intriguingly, that loss of PPARδ in joint tissues may modulate this
outcome.
Our study also demonstrated that obesity-induced pain behaviors were more consistent in
female compared to male mice. These findings are supported by both clinical and basic
research, which show that the prevalence of chronic pain is higher in females than males79.
While several underlying mechanisms have been suggested, including cognitive and
sociocultural differences, differences in gonadal sex hormones also play a biological role
in pain79. Several studies establish the pro-nociceptive role of estrogen that is mediated
through its receptors, estrogen receptor α (ERα) and estrogen receptor β (ERβ)80. In normal
mice and in a model of inflammatory pain, global deletion of ERα or ERβ eliminated
underlying sex differences seen in mechanical sensitivity80. In addition to the sexual
dimorphism observed in pain-related behaviors, sex differences were also seen in the
progression of structural IVD degeneration induced by the western diet. Male mice fed the
western diet showed accelerated IVD degeneration compared to chow controls; a result not
observed in female mice. While the underlying mechanism are currently unknown,
previous studies have illustrated that female mice fed a high-fat diet have an increased
capacity for adipocyte enlargement, resulting in reduced adipose tissue inflammation, fat
deposition in non-adipose tissues, and better insulin sensitivity compared to male mice81.
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These sex-dependent metabolic phenotypes may modulate the systemic effects of obesity
and thereby alter the progression of structural IVD degeneration. Furthermore, sex may
also impact PPARδ signaling. Estrogen receptors (ERα, ERβ) can inhibit PPARα and
PPARγ signaling through competitive binding of hormone response elements and reduced
availability of coactivators82,83. Although not examined to date, a similar interaction may
exist between estrogen receptors and PPARδ, potentially impacting the results of this study.
Taken together, this study highlights the complex, and context-dependent role of PPARδ
within the IVD and joint tissues. Our analysis demonstrates that deletion of PPARδ in
cartilaginous tissues plays a protective role in age-associated IVD degeneration yet does
not protect against obesity-associated IVD degeneration or osteoarthritis. These findings
underscore potential differences in the pathogenesis of joint degeneration and associated
pain based on the underlying cause. As many promising basic science discoveries fail to
enter clinical use84, these differences should be further explored in the context of IVD
degeneration and applied to clinical trials and basic research.
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4.7

Supplementary Figures

Figure 4.10, Supplementary Figure 1: Schematic overview of PPARδ diet study
design.
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Figure 4.11, Supplementary Figure 2: Effect of PPARδ activation on metabolic gene
expression in IVD explant cultures.
SYBR-based real-time qPCR analysis of gene expression in IVD explants incubated for
(A) 4 days or (B) 7 days with increasing concentrations of the PPARδ agonist GW501516.
Expression of Abca1, Cpt1a, Gsta4, and Insig1 were not altered by PPARδ agonist
treatment at either time point. After 7 days of treatment, a significant increase in the
expression of Txnip was induced by 0.01 μM agonist treatment. Values are represented as
the mean ± SEM. (n= 3-5 independent trials). *P<0.05 compared to DMSO control by oneway ANOVA with Tukey’s test.
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Figure 4.12, Supplementary Figure 3: Effect of PPARδ agonism on extracellular
matrix in IVD explant cultures.
(A) Representative sections of IVD explants treated for 4 days with DMSO or 1 µM PPARδ
agonist GW501516 stained with Safranin-O/Fast Green. Explants treated with GW501516
show less intense safranin-o staining within the NP, suggesting proteoglycan loss. (B) The
amount of sulfated glycosaminoglycan (s-GAG) released into the media and remaining
within IVD explants was quantified using the dimethylmethylene blue assay. Data is
presented as mean ± 95% CI (n= 3 independent trials, P < 0.05 versus DMSO). SYBRbased qPCR analysis of (C) matrix remodeling genes and (D) extracellular matrix genes in
IVD explants after 4 days incubation with GW501516 or vehicle control (DMSO). No
significant difference in gene expression was detected for any of the genes investigated.
Expression was normalized to the expression of the house-keeping gene Rps29 and
expressed relative to DMSO control. Data is presented as mean ± 95% CI (n= 5-6
independent trials, P < 0.05 versus DMSO).
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Figure 4.13, Supplementary Figure 4: Tail Flick assay.
To determine the anti-nociceptive response of tramadol, the latency of the tail flick
response was assessed prior to (baseline) and after IP injection of tramadol (50 mg/kg). (A)
The tail flick response was elicited by applying radiant heat to the tip of the tail and the
withdrawal time recorded. A cutoff time of 12 seconds was used to avoid tissue injury. (B)
The response to thermal stimulation was plotted as the percentage of maximal possible
effect (%MPE) which is calculated as [(T1 – T0)/(T2-T0)] x 100. T0 and T1 were the tail
flick latency times before and after administration of tramadol and T2 is the cutoff time.
No significant differences were seen between any condition. n=9-13 animals per sex,
genotype, and diet. Data are plotted mean ± 95% CI.
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Figure 4.14, Supplementary Figure 5: Tramadol induced a slight sedative effect in
male mice.
Spontaneous locomotion was measured over 10 min to assess the sedative effects of
tramadol. (A) In male mice, tramadol (50 mg/kg I.P.) had a slight sedative effect leading
to reduced spontaneous movement in both diet conditions, a change detected to a greater
extent in chow-fed mice compared to mice fed the western diet. (B) In female mice,
average spontaneous locomotion increased with the addition of tramadol. Graphs on the
left show the percent of baseline, which represents the distance travelled following
tramadol treatment normalized to the pre-treatment (baseline) values for each animal.
Graphs on the right show the distance travelled for mice in each group in the absence and
following administration of tramadol. n=9-13 animals per sex, genotype, and diet. Data
are plotted mean ± 95% CI. **P<0.01 between diets in each treatment group; indicates
significant (P<0.05) tramadol-induced differences in distance travelled for mice fed the
chow (black) or western (red) diet by 2-way ANOVA with Tukey’s test.
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Table 4.2, Supplementary Table 1: Realtime qPCR primer sequences
Pdk4 Fwd
Pdk4 Rev
Angptl4 Fwd
Anptl4 Rev
Cidea Fwd
Cidea Rev
Ppard Fwd
Ppard Rev
Col1a1 Fwd
Col1a1 Rev
Col2a1 Fwd
Col2a1 Rev
Acan Fwd
Acan Rev
Mmp3 Fwd
Mmp3 Rev
Mmp13 Fwd
Mmp13 Rev
Adamts4 Fwd
Adamts4 Rev
Il-1b Fwd
Il-1b Rev
Il6 Fwd
Il6 Rev
Bdnf Fwd
Bdnf Rev
Adamts5 Fwd
Adamts5 Rev
Abca1 Fwd
Abca1 Rev
Cpt1a Fwd
Cpt1a Rev
Gsta4 Fwd
Gsta4 Rev
Insig1 Fwd
Insig1 Rev
Txnip Fwd
Txnip Rev

Primer Sequence 5’ → 3’
CCGCTTAGTGAACACTCCTTC
TGACCAGCGTGTCTACAAACT
CATCCTGGGACGAGATGAACT
TGACAAGCGTTACCACAGGC
TGGAAAAGGGACAGAAATGG
TCTCGTACATCGTGGCTTTG
TCCATCGTCAACAAAGACGGG
ACTTGGGCTCAATGATGTCAC
CTGGCGGTTCAGGTCCAAT
TCCAGGCAATCCAGGAGC
GCACATCTGGTTTGGAGAGACC
TAGCGGTGTTGGGAGCCA
CTGGGATCTACCGCTGTGAAG
GTGTGGAAATAGCTCTGTAGTGGAA
TTGTCCCGTTTCCATCTCTCTC
TTGGTGATGTCTCAGGTTCCAG
CTTCTTCTTGTTGAGCTGGAACTC
CTCTGTGGACCTCACTGTAGACT
GAGGAGGAGATCGTGTTTCCAG
CAAACCCTCTACCTGCACCC
CCCTGCAGCTGGAGAGTGTGGA
TGTGCTCTGCTTGTGAGGTGCTG
TCTCTGCAAGAGACTTCCATCCAGT
AGTAGGGAAGGCCGTGGTTGTCA
TCATACTTCGGTTGCATGAAGG
GACCTCTCGAACCTGCCC
GGAGCGAGGCCATTTACAAC
GCGTAGACAAGGTAGCCCACTTT
GCTACCCACCCTACGAACAA
GGAGTTGGATAACGGAAGCA
TCAATCGGACCCTAGACACC
TGGTAGGAGAGCAGCACCTT
GCTGGAGTGGAGTTTGAGGA
TGTGTCAGCATCATCCCATC
GACGAGGTGATAGCCACCAT
TGGCCCATTCTCTCTTGAAC
GGTCTCAGCAGTGCAAACAG
AGCTCGAAGCCGAACTTGTA
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Table 4.3, Supplementary Table 2. Association between behavioral indicators of
pain and histological joint damage.
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Chapter 5

5

General Discussion

5.1

Overview

The overall objective of my thesis was to assess how mechanical loading and obesity
impact intervertebral (IVD) physiology. Despite being established risk factors for the
development of both IVD degeneration and related back pain, the biological mechanisms
by which these factors contribute to disease initiation and progression remain elusive. To
address this, we utilized mouse models to understand the biological impact of both
mechanical loading and obesity on the IVD. In order to contextualize our findings within
systemic changes to musculoskeletal health, we also investigated the impact of these risk
factors on the knee joint, as there are similarities between the IVD degeneration and knee
osteoarthritis (OA) in terms of both risk factors and pathological processes1.
We first investigated the impact of mechanical loading, specifically whole-body vibration
(WBV) on IVD health in Chapter 2. This study built upon previous research from our lab
which demonstrated that whole-body vibration (WBV) induces IVD degeneration and knee
osteoarthritis (OA) in as little as 4 weeks in a mouse model, using vibrational parameters
that model those used clinically2,3. Previous studies were however limited to the analysis
of only young, male mice of a single outbred stock (CD1) and do not accurately recapitulate
the diverse human population currently using WBV platforms. To determine whether these
findings would be consistent in another mouse model, I exposed inbred C57BL/6 mice to
the same vibrational parameters as the previous studies2,3 for either 4 or 8 weeks. Analysis
of these results revealed that the same vibrational parameters previously shown to induce
histopathological IVD degeneration and knee OA in CD1 mice did not affect joint health
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in C57BL/6 mice. Furthermore, molecular changes seen at the transcriptional level in the
IVD were not observed in the C57BL/6 mice. From this initial study, we concluded that
C57BL/6 mice were resistant to WBV-induced joint degeneration, at least at the specific
vibrational parameters used.
Next, I investigated the impact of diet-induced obesity on IVD degeneration and associated
pain in Chapter 3. Despite the established clinical association between obesity, IVD
degeneration and low back pain4,5, there have been no studies to directly investigate the
impact of diet-induced obesity on IVD degeneration and pain. To address this, I
characterized the longitudinal impact of diet-induced obesity on pain-related behavior and
structural IVD degeneration in a mouse model. In this study, male wild-type C57BL/6N
mice were randomized into one of three diet groups (chow control, high-fat, or a highfat/high-sugar western diet) and fed the experimental diets for 12, 24, 40 or weeks. At
endpoint, all mice were assessed for behavioral indicators of pain as well as histological
IVD degeneration. We demonstrated that diet-induced obesity led to pain-related behaviors
in as little as 12 weeks, with behavioral differences persisting until the 40-week timepoint.
Histopathological analysis showed that diet-induced obesity did not affect IVD health until
the 40-week timepoint, where early degenerative changes were observed. At the molecular
level, mice fed the western diet showed increased expression of Il-1b and Ptgs2 in the IVD
at the 24-week timepoint, while mice fed a high-fat diet showed increased expression of Il6, Ptgs2, Bdnf, and Adamt5 at the 40-week timepoint. Since behavioral indicators of pain
preceded structural and molecular alterations to the IVD, we then investigated other
potential mechanisms to explain the pain phenotype observed. We quantified markers of
neuroinflammation and systemic inflammation, as they have been previously shown to

182

impact pain sensitivity6,7. While no significant differences were found in the levels of most
markers investigated, mice fed the high-fat and western diet tended to show elevated levels
of inflammatory cytokines and neuroinflammation, which could impact the pain phenotype
seen.
Lastly, we investigated the role of peroxisome proliferator-activated receptor delta
(PPARδ) in the IVD and its role in age- and diet-associated IVD degeneration in Chapter
4. Since previous studies have demonstrate that PPARδ activation has a deleterious role in
other cartilaginous joints8, we sought to determine its role in the IVD. Intact IVDs were
isolated and treated in organ culture with the synthetic PPARδ agonist GW501516. Gene
expression analysis showed upregulation of known PPARδ target genes (Pdk4 and
Angptl4)9, indicating that PPARδ was functional and responsive in IVD tissues. Similar to
articular cartilage8, PPARδ agonism appeared to decrease proteoglycan staining in the NP;
however, no differences were seen in the expression of matrix degrading enzymes. PPARδ
expression was then measured in different compartments of the IVD, demonstrating a 2fold greater expression of Ppard in the AF compared to the NP. To assess the role of
PPARδ in the IVD, we characterized mice with cartilage-specific deletion of PPARδ in
age-associated IVD degeneration. At 14 months-of-age loss of Ppard did not alter the gross
histological features of the IVD; however, gene expression analysis showed an
upregulation of matrix metalloproteinases (Mmp3, Mmp13) and Il-1b which are typically
associated with accelerated degeneration10,11. At 25 months-of-age, male Ppard KO mice
appeared to be protected from age-associated degeneration observed in WT mice; however,
differences in histopathological scores were not significant.
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Given that PPARδ ligands are dysregulated in obesity12, and the potential protective role
of PPARδ inactivation in age-associated IVD degeneration, we then investigated the effects
of PPARδ inactivation in a model of western diet-induced obesity. After 50 weeks on the
western diet, male Ppard KO mice showed significantly greater IVD degeneration than
chow-fed controls. Moreover, a greater proportion of Ppard KO mice on the western diet
showed moderate-severe IVD degeneration than WT mice on the western diet, although
average histopathological scores were not significantly different between the two groups.
These findings suggest that, contrary to our hypothesis, loss of Ppard may accelerate
obesity-induced IVD degeneration. Of note, neither PPARδ inactivation nor western dietinduced obesity impacted IVD degeneration in female mice, indicating important sexspecific effects. To determine whether IVD degeneration was associated with pain, we
carried out a series of behavioral assays and demonstrated that western diet induces pain
related behavior in both male and female mice, with a more consistent response seen in
females. Interestingly, despite significant increases in joint degeneration, male Ppard KO
mice fed the western diet did not show pain-related behaviors when compared to chow-fed
control. While these findings need to be further explored, they suggest that PPARδ may
contribute to painful joint degeneration.

5.2

Contributions and significance of findings

Back pain is an extremely prevalent, debilitating condition that has a significant impact at
both on the individual and societal level13–15. The aim of this thesis was to answer several
key questions surrounding the role of two environmental risk factors associated with IVD
degeneration and associated pain using the mouse as a preclinical model. Our studies
highlight several consistent findings which are important considerations in future clinical
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and pre-clinical research. First, our studies underscore that the relationship between
environmental risk factors (e.g. mechanical loading, obesity), IVD degeneration, and back
pain is complex. While these risk factors may drive IVD degeneration and pain in certain
circumstances, their effects on IVD health is influenced by interactions with nonmodifiable risk factors such as age, genetic background, and sex (i.e. effects of WBV on
CD-1 versus C57BL/6 mice, obesity-induced IVD degeneration in male versus female
mice). Second, although clinical or histological features of IVD degeneration may be
similar at endpoint, disease pathogenesis may be driven by entirely different mechanism
based on the degeneration-inducing catalyst (i.e. PPARδ regulates age but not obesityinduced IVD degeneration). Lastly, our studies highlight the importance of taking an
integrated approach (assessing both musculoskeletal and nervous tissues) when
investigating the relationship of these risk factors with joint degeneration and pain.
Mechanical loading and obesity impact other tissues including articular joints, connective
tissue, and the nervous system, which may interact with, and contribute to both structural
IVD degeneration and pain (Figure 5.1). Aside from these general themes, each chapter
independently contributes important findings illustrating the role of mechanical loading
and obesity in the initiation and progression of IVD degeneration and associated pain.
In Chapter 2, we present work in which we show that C57BL/6 mice are resistant to WBVinduced joint damage using vibrational parameters that have been shown to induce joint
damage in CD1 mice, and model those used clinically. While this data was negative, it
highlights the need for more comprehensive evaluations of the direct impact of WBV on
joint health in the human population. Vibrational parameters such as duration, frequency,
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and acceleration, along with the direct load experienced by the joints may determine
whether WBV therapy is therapeutic or detrimental.
Chapters 3 & 4 present novel data characterizing the impact of diet-induced obesity on
IVD degeneration and pain over time in a mouse model. Despite being one of the largest
modifiable risk factors for the development of IVD degeneration and back pain4,5, no
studies have directly assessed whether diet-induced obesity accelerates IVD degeneration,
back pain, or investigated biological mediators underlying this association. Our studies
show that diet-induced obesity leads to behavioral indicators of pain starting at the 12-week
timepoint, yet histological indicators of IVD degeneration are not seen until the 40-week
timepoint, increasing in severity following 50 weeks. The chronology of these findings
raises the possibility that IVD degeneration may not be the primary causative factor in
some cases of obesity-associated LBP. While speculative, it could be postulated that
systemic inflammation caused by obesity directly alters the neural excitability, leading to
a pain response in absence of overt joint tissue damage. This systemic inflammation,
coupled with inactivity because of pain, may accelerate the IVD degeneration in this model.
Aside from obesity-related inflammation, dyslipidemia, hyperglycemia, and hypertension
may also impact musculoskeletal and nervous tissues and contribute to the findings
observed (Figure 5.1). While the etiology remains elusive, our findings demonstrate that
diet-induced obesity contributes to both structural IVD degeneration and pain in a mouse
model. These findings lay the groundwork for future studies investigating potential
biological mechanisms underlying these associations.
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Figure 5.1: Schematic illustrating the proposed contributions of mechanical loading
and obesity to IVD degeneration and associated pain.
This thesis highlights the complex interaction between environmental risk factors (i.e.
mechanical loading and obesity) and non-modifiable factors (i.e. age, genetic background,
sex) on IVD degeneration and associated pain. In addition to affecting the IVD directly,
these factors can also impact other tissues (i.e. other joints, muscles, bone, nervous tissues)
which may contribute to both structural IVD degeneration and associated pain. Solid lines
indicate direct assessments made in this thesis, and dashed lines indicate potential
contributions to IVD degeneration and pain not directly investigated in this thesis.
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In Chapter 4, we investigate the nuclear receptor PPARδ as a potential mediator of ageand obesity-associated IVD degeneration. Our findings demonstrated that similar its role
in articular cartilage, deletion of PPARδ may protect against age-associated IVD
degeneration16. However, deletion of PPARδ did not protect from obesity-induced IVD
degeneration or knee OA. In fact, on the western diet a higher proportion of Ppard KO
mice showed moderate/severe IVD degeneration than did WT mice. These findings
indicate that PPARδ plays a context dependent role in the IVD (Figure 5.2) and highlight
that the etiology of IVD degeneration is likely multifactorial and providing evidence that
disc degeneration should be treated as a group of diseases with separate pathogenesis but
a common radiological/histological endpoint. In addition to evaluating the impact of
PPARδ on the IVD health, this study also illustrates the importance of assessing the
correlation between structural IVD degeneration and pain, and sex-related differences.
Obesity induced by the western diet accelerated IVD degeneration in male mice but did
not significantly impact IVD health in female mice. In contrast, female mice showed more
consistent pain-related behaviors on the western diet than male mice, despite having no
significant IVD degeneration.

5.3

Limitations of research

As with other MSK tissues, human IVD tissue is difficult to obtain, especially healthy
tissues or those corresponding to the early stages of disease. As such, animal models are
often used to understand the pathophysiology of IVD degeneration and associated back
pain17. Rodents are the most frequently used small animal model based on their ease of use,
low cost, and the ability to manipulate their genome17. Despite their widespread use, some
limitations associated with the use of mouse models include the persistence of notochordal
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Figure 5.2: Schematic overview of proposed context-dependent role of PPARδ in the
IVD.
Our findings highlight the complexities of nuclear receptor signaling in the IVD and other
cartilaginous tissues. While PPARδ deletion was protective in a model of age-associated
IVD degeneration, it did not appear to play a protective role in a model of obesity-related
IVD degeneration. Furthermore, a higher proportion of Ppard KO mice showed more
severe IVD degeneration on the western diet than WT mice, suggesting that in the context
of obesity loss of PPARδ may accelerate IVD degeneration.
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cells in the NP into adulthood, and altered mechanical loading as reviewed recently 18.
Although there is an obvious size difference between human and mouse IVDs, and the
limitations mentioned above need to be acknowledged, both species have similar geometry,
biomechanics and IVD extracellular composition 19–21.
In Chapter 2, we show that C57BL/6 mice are resistant to WBV-induced joint
degeneration, in contrast to previous studies by our group demonstrating the deleterious
effects of WBV in CD-1 mice3,22. However, these experiments were performed with only
a single protocol of WBV and little is known regarding what parameters of WBV (i.e.
frequency, amplitude, duration of exposure) may be beneficial or detrimental to joint
health. Previous studies have reported that vibration magnitude is attenuated differently in
different stains of mice23, and that the resonant frequency range also differs between strains
of mice23, raising the question about what loads are being experienced by the joint tissues
themselves. While mechanical loading is a key regulator of IVD cell homeostasis, cells can
only respond to local mechanical forces, and can have differential responses dependent on
both the cell type and loading parameters applied24–27. If the local mechanical load
experienced by the joint tissues differed between CD1 and C57BL/6 mice, this could
explain the differential response. Additional factors including baseline bone properties or
differences in posture have also been shown to impact WBV transmission through the body
and could be further explored to better understand the differences observed between the
strains of mice28,29.
In Chapter 3, we establish the effect of diet-induced obesity on IVD degeneration and
pain. Designed as a proof-of-concept, this study had several limitations. First, only male
mice were used. Studies in humans have shown that females have a higher prevalence of
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spinal disorders and chronic pain conditions than males30,31. Second, this study was limited
to only a single formulation of the high-fat and western diets, limiting the generalizability
of our results. While not investigated in the context of the IVD, recent studies examining
the effects of diet-induced obesity on knee OA show that dietary composition is an
important determinant of OA progression in obesity. Diets high in saturated fatty acids or
ω-6 polyunsaturated fatty acids (PUFAs) induce more severe metabolic dysregulation and
OA progression than diets enriched with ω-3 PUFAs32. Aside from fat, diets high in sucrose
also accelerate OA progression independent of weight gain33. A third limitation is the use
of behavioral assays to assess pain. While many of the behaviors examined are altered in
experimental pain models, most can be impacted by additional biological and psychosocial
factors34,35. In systemic conditions such as obesity, the impact of co-morbidities on
behavioral outcomes should be considered. For example, grip force during axial stretch
and tail suspension assays have been shown to measure of discogenic back pain36, but are
also used to assess muscle strength and the effects of anti-depressants, respectively37,38.
Moreover, other joints should also be assessed, as obesity has been shown to globally
impact joint health which may contribute to the pain-related behavior observed39. Finally,
it is becoming increasingly accepted that IVD degeneration is not just a disease of the IVD,
but also the adjacent structures including the muscle, ligaments, vertebrae and facet joints1.
Understanding the direct effects of obesity on these structures, and their relation to IVD
degeneration and pain, is an important consideration for future studies.
In Chapter 4, we established the effect of PPARδ deletion in the IVD using both age and
obesity-induced models of degeneration. One limitation of this study was the Cre-driver
used. Using fluorescent reporter mice, our group has shown that Col2-Cre targets the NP,
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inner 2/3 of the AF, and the CEP. However, in addition to effecting recombination in the
IVD, the Col2-Cre is also active in cartilaginous tissues of all joints as well as synovial
fibroblasts and some osteoblasts40,41. Given that many of the behavioral indicators of pain
would be impacted by degeneration associated changes in other joints42, use of the Col2Cre impairs our ability to draw conclusions about the relative contribution of IVD changes
and the precise role of PPARδ to the pain-related phenotype observed. A second limitation
common to all studies is the ability to assess tissue-specific changes within the IVD. In all
three studies, gene expression analysis was conducted on intact IVDs. Given that the IVD
is a heterogenous structure, composed of distinct tissues with diverse cellular phenotypes
in each tissue43, the tissue-specific effects of each intervention were evaluated.
In Chapter 4 we used an ex vivo IVD organ culture system to evaluate the effect of PPARδ
activation. Organ culture has been suggested as a physiologically relevant model in which
cells remain in their endogenous microenvironment, while in vitro conditions are
modulated17. One limitation of the organ culture system relates to the heterogeneity of the
IVD43 and the inability to differentiate the role of PPARδ activation within each cell type
(NP, AF, and CEP). Although monolayer culture would allow for cell type specific
experimentation, expansion of primary NP and AF cells in monolayer culture has been
shown to alter cellular processes and phenotype17.

5.4

Future Directions

The findings of this thesis can be further expanded on in several ways, some of which
address the limitations detailed above. To better understand the effects of vibrational
loading on the IVD it would be important to quantify the transmission of vibration within
joint tissues in vivo during WBV. One potential method to quantify site-specific vibrational
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amplitude in live mice is through non-invasive x-ray imaging of mice carrying zirconium
dioxide fiducial marker beads embedded around the joint tissues (i.e. spine and knee joint)
during WBV. Similar protocols have been previously used to assess the effects of cyclic
loading on strain in the porcine anterior cruciate ligament44. This study would allow us to
assess the effects of posture, soft tissue dampening and resonance effects on the
transmission of vibration to specific anatomical locations (i.e. spine, knee). Site-specific
findings could then be correlated to the biological effects of WBV characterized in each
respective tissue. Future work can also follow up on putative biological pathways
underlying this association using transcriptomics and proteomic approaches.
To further characterize the role of diet-induced obesity in IVD degeneration and associated
pain, future studies should take a more integrated approach given the systemic effects of
obesity on the body. In addition to investigating structural joint degeneration within the
IVD, the effects of obesity should be directly assessed in surrounding spinal tissues
including muscles, ligaments, and the facet joints to determine if their dysfunction
contributes to IVD degeneration and/or axial pain. In the context of pain, the impact of
obesity should be assessed longitudinally through a repeated measures design, where
animals undergo behavioral testing prior to randomization and at regular intervals
throughout the time course of the study (e.g. every 4 weeks). These findings would allow
us to determine the point at which pain-related behaviors initiated and whether they
persisted in each animal. These findings could then be correlated with non-invasive, in vivo
assessments of joint degeneration such as T2-weighted MRI, which has been shown to
detect degenerative changes in both the IVD and articular cartilage of the knee in rodent
models45,46. Pathological changes within the peripheral and central nervous system should
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be more thoroughly examined to determine potential mechanisms underlying the pain
response associated with diet-induced obesity. Examples include quantification of markers
of peripheral nerve injury (ATF3) in the dorsal root ganglia (DRG) and the production of
immune and glial mediators (e.g. TNFα, IL-1β, BDNF) in the spinal cord47,48.
To more robustly characterize the cellular pathways responsible for the association
between obesity and IVD degeneration, a systems biology approach using multiple -omics
technologies (i.e. epigenomics, transcriptomics, proteomics, metabolomics) could be used
to independently assess isolated NP and AF tissues in this model. To specifically address
the heterogeneity of cell types within the IVD, single-cell RNA sequencing could also be
used. Finally, future studies could also be designed to investigate potential biological
pathways or dietary constituents that are associated with accelerated IVD degeneration and
pain.
Characterization of the role of PPARδ in age- and obesity-associated IVD degeneration
was limited by the transgenic model used. To address the off-target effects associated with
use of the Col2-Cre, future studies could be conducted using the Noto-Cre mouse strain,
which our group has been shown to be specific for notochord-derived cells of the NP49. To
address tissue specific-differences, AF-specific Cre-drivers such as Gdf5-Cre or Scx-Cre
may also be used, although these are also associated with off-target effects in other MSK
tissues50,51. In addition to using a systems biology approach (as detailed above) to assess
the effects of PPARδ agonism in the NP and AF, the interplay between different nuclear
receptors should also be investigated. There is substantial overlap between nuclear receptor
signaling52, and given the similarity between the ligands and DNA binding domains
between the PPAR subtypes53, the consequence of deleting PPARδ on PPARα and PPARγ
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signaling should be investigated. To do so, chromatin immunoprecipitation with
subsequent DNA sequencing (ChIP seq) could interrogate alternate binding of PPARα and
PPARγ when PPARδ is no longer present.
Taken together, the results of this thesis highlight the complex nature of mechanical
loading and obesity on IVD health. Furthermore, these studies highlight the importance of
assessing for pain in conjunction with structural IVD degeneration as they are not always
mutually exclusive. Importantly, for effective clinical translation, potential therapeutic
targets should be evaluated in multiple different preclinical models of IVD degeneration
that consider factors such as genetics, sex, and age.
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